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ISG15 is an interferon-induced and anti-viral ubiquitin-like protein (Ubl).  Ube1L, 
UbcH8, and Herc5 have been identified as the E1-E2-E3 enzymes for ISG15 conjugation, 
and, like ISG15, their expression is induced by type I interferons.  Although Herc5 is the 
major E3 for ISG15, over 300 proteins have been identified as ISG15 target proteins in 
interferon-stimulated cells.  In this work, I address two aspects of the human ISG15 
conjugation system: 1) the specificity of the Ube1L-UbcH8 interaction and 2), the basis 
of substrate recognition by Herc5.  Regarding the selection of UbcH8 by Ube1L, my 
experiments show that although UbcH8 had been reported to function as an E2 for both 
Ub and ISG15, UbcH8 is preferentially activated by Ube1L compared to Ube1 (E1Ub).  
The basis of this preference is a result of specific interactions between the ubiquitin-fold 
domain (UFD) of Ube1L and the amino-terminal α1-helix and β1−β2 region within 
UbcH8. Examination of the interferon-induced and transfected expression levels of 
UbcH8, combined with the kinetic constants, suggest that UbcH8 is unlikely to function 
 vii 
as a Ub E2 in most cell lines.  In examining the selection of target proteins by Herc5, I 
show that the range of substrates extends far beyond the proteins identified in proteomics 
studies and includes many exogenously expressed foreign proteins.  Furthermore, I show 
that ISG15 conjugation is restricted to newly synthesized pools of proteins and Herc5 is 
associated with polyribosomes.  I propose a model for ISGylation in which Herc5 broadly 
modifies newly synthesized proteins in a co-translational manner and suggest that, in the 
context of an interferon-stimulated cell, newly translated viral proteins may be primary 
targets of ISG15.  Consistent with this, I show that ISGylation of human papillomavirus 
(HPV) L1 capsid protein has a dominant-inhibitory effect on the infectivity of HPV16 
pseudoviruses. These discoveries have greatly increased our understanding of the 
mechanism of ISG15 pathway and provide a framework for establishing an in vitro 
ISG15 conjugation system and further examination of the anti-viral function of ISG15. 
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Chapter 1: Introduction 
 
1.1 A BRIEF OVERVIEW OF THE UBIQUITIN SYSTEM 
In 2004, the Nobel Prize in Chemistry was awarded to Aaron Ciechanover, 
Avram Hershko and Irwin Rose for their discovery of the ubiquitin system and its role in 
regulated protein degradation.  The lysosome, discovered in the 1950s, was assumed to 
mediate all protein degradation, however several lines of evidence suggested an 
additional ATP-dependent mechanism existed as well (Ciechanover, 2009).  Hershko, 
Ciechanover, and colleagues published the first of many papers in 1978 on the selective 
post-translational modification of cellular proteins with a 8.5 kDa protein now known as 
ubiquitin (Ciehanover et al., 1978).  They discovered an ATP-dependent system in which 
a protein tagged with ubiquitin is selectively degraded by the proteasome.  Today, 
ubiquitination is known to function in a wide range of cellular processes, including DNA 
repair, transcription, endocytosis, membrane transport, protein localization, and antigen 
processing.   
1.1.1 Conjugation of Ubiquitin 
Ubiquitin (Ub) is covalently conjugated to proteins through amide bonds formed 
between their terminal carboxyl groups and, in most cases, ε-amino groups of lysine 
residues of target proteins.  The Ub conjugation pathway consists of E1, E2, E3 and de-
ubiquitinating enzymes (DUBs) (Figure 1.1) (Passmore and Barford, 2004).  Ub is 
expressed as an inactive precursor and before it can be conjugated to a target protein a 
DUB must cleave Ub to reveal a Gly-Gly motif at the C-terminus.  Once processed, E1 
forms an ATP-dependent Ub-adenylate followed by an enzyme-bound Ub-thioester at the 
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active site cysteine of the E1.  The activated E1 then binds a specific E2 enzyme and 
transfers Ub to the E2 active-site cysteine in a transthiolation reaction, preserving the Ub-
thioester linkage.  The Ub charged E2 enzyme dissociates from the E1 and binds an E3 
ligase that facilitates transfer of Ub to a target protein.   Ubiquitination can be reversed 
when DUBs hydrolyze the isopeptide bond between Ub and the substrate or between two 
Ub molecules.  This reversal by DUBs functions to recycle Ub, edit the Ub chain 
topology of target proteins, and rescue proteins from proteasome-mediated degradation 
(Love et al., 2007).  In humans, there are two E1s (Uba1 and Uba6), approximately 60 
E2s, 100 DUBs, and between 600-1000 E3s for the Ub pathway (Rape, 2009). 
Once the target protein has been selected, ubiquitin is added either as one 
molecule (monoubiquitination and multi-monoubiquitination) or as a chain of molecules 
(polyubiquitination).  Ubiquitin has seven lysines (K6, K11, K27, K29, K33, K48, K63) 
available to link with other ubiquitin molecules resulting in homotypic chains or mixed-
linkage chains (Kim et al., 2007).  All seven lysines of ubiquitin have been shown to 
form chains in vivo, however the function of some chain types is still unknown (Peng et 
al., 2003).  K48-linked chains have been well established as the main chain type involved 
in proteasomal degradation, but all other chain types (with the exception of K63-linked 
chains) are capable of targeting proteins to the proteasome in vivo (Xu et al., 2009).  For 
example, Xu et al. demonstrated that K11-linked chains were shown to be required for 
targeting misfolded proteins in the ER for proteasomal degradation.  Although K63-
linked chains do not signal protein degradation, they function in processes ranging from 
cell surface receptor internalization to signaling events leading to NF-κβ activation 
(Bennett and Harper, 2008; Hayden and Ghosh, 2008; Mukhopadhyay and Riezman, 
2007).  Recently, unanchored K63-polyubiquitin chains have been shown to be required 
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for the activation of RIG-I, a viral RNA detector involved in the innate immune response 
(Zeng et al., 2010).  Physiological roles for monoubiquitination include DNA repair and 
endocytosis (Haglund and Dikic, 2005; Hicke, 2001).   
 
Figure 1.1: The Ubiquitin Pathway.   
1.1.2 E1 activating enzymes 
Structural studies of E1 enzymes have identified three functional domains: 1) an 
adenylation domain which binds Ub and ATP and catalyzes adenylation of the C-
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terminus of Ub forming Ub~AMP, 2) a cysteine domain which contains the catalytic 
cysteine, and 3) a ubiquitin-fold domain (UFD) which recruits E2 enzymes (Schulman 
and Harper, 2009).  The catalytic reaction cycle begins with the formation of Ub~AMP 
which is then attacked by the catalytic cysteine to form an enzyme-bound Ub-thioester.  
Adenylation of a second Ub molecule occurs resulting in a doubly loaded E1 enzyme that 
presents the UFD for interaction with the E2 enzyme.  Transthiolation occurs, E2~Ub is 
released, and remaining Ub~AMP serves as the precursor the next reaction cycle.  The E1 
enzyme must undergo major conformational changes during this process.  For example, 
the site of Ub~AMP formation is widely separated from the catalytic cysteine.  Recent 
structures of SUMO and its E1 reveal that once SUMO~AMP is formed, the cysteine 
domain rotates 130 degrees and secondary structure must refold for E1~SUMO thioester 
formation (Olsen et al., 2010). E1 active site remodeling may also be required to facilitate 
transfer of Ub/Ubl from the E1 cysteine to the E2 cysteine.  A complete understanding of 
E1 conformational changes is important for the development of small molecule 
inhibitors.  For example, the Nedd8 pathway is involved in cell cycle control, and a 
recently developed Nedd8 E1 inhibitor is currently in phase I clinical trials for solid 
tumor malignancies (Soucy et al., 2009).  The work by Olsen et al. will aid in developing 
additional E1 small molecule inhibitors in the future.   
1.1.3 E2 conjugating enzymes 
All E2 conjugating enzymes consist minimally of a core ubiquitin-conjugating 
domain (UBC) of approximately 150 residues, one of which is the catalytic cysteine 
(Pickart, 2001).  E2 enzymes must bind E1 and E3 enzymes however, these events are 
mutually exclusive (Eletr et al., 2005; Eletr and Kuhlman, 2007).  Structures of E2 
enzymes in complex with either an E1 or E3 enzyme reveal the E2 N-terminal α1-helix 
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interacts with both the E1 and E3 enzymes (Bencsath et al., 2002; Eletr and Kuhlman, 
2007; Huang et al., 2005; Huang et al., 1999; Reverter and Lima, 2005).  In addition, 
some studies have shown E1 enzymes prefer uncharged E2s, while E3 enzymes prefer 
Ub-charged E2 enzymes (Hershko et al., 1983; Kawakami et al., 2001; Pickart and Rose, 
1985; Siepmann et al., 2003).  While the α1-helix is important for both interactions, the 
E1-E2 interaction also requires the β1-β2 region whereas the E2-E3 interaction requires 
additional residues from Loops 4 and 7 of the E2 enzyme.  For example, a phenylalanine 
residue in Loop 4 is important for the E2 interaction with both HECT and RING E3 
ligases, while a tryptophan residue in Loop 7 is important for RING E3 interactions 
(Huang et al., 1999; Martinez-Noel et al., 1999; Zheng et al., 2000).  Until recently, E2 
enzymes were considered to function only as “carriers” of Ub between the E1 and E3.  
Many new studies have shown that some E2 enzymes play a role in the type and length of 
Ub chain formed on substrates (Ye and Rape, 2009).  This function is limited to E2s that 
interact with RING E3s most likely because RING E3s are docking proteins with no 
catalytic activity.     
1.1.4 E3 ligase enzymes 
E3s function minimally as docking or scaffolding proteins, binding both the 
activated E2 and a substrate protein.  There are two major types of E3 ligases: RING E3s 
and HECT (Homologous to E6AP C-terminus) E3s.  In the case of the HECT E3 ligases, 
the E2 transfers Ub to the active-site cysteine of the E3, with the E3 directly catalyzing 
the final transfer to the target protein.  Alternatively, RING E3 ligases have no catalytic 
activity and instead facilitate the transfer of Ub from the E2 directly to the target protein.  
In humans, there are 28 HECT E3 ligases compared to over 600 RING E3 ligases 
(Deshaies and Joazeiro, 2009; Rotin and Kumar, 2009).    
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RING E3 ligases 
The RING domain is composed of two zinc atoms bound to cysteines and 
histidines to form a cross-brace which stabilizes the RING E3 and mediates the 
interaction with the E2 enzyme (Deshaies and Joazeiro, 2009).  Cbl, a monomeric RING 
E3 ligase, contains a phosphotyrosine-binding domain (PTB) upstream of its RING finger 
domain that allows Cbl to recognize tyrosine-phosphorylated target proteins (Joazeiro et 
al., 1999). Recently STUbls (SUMO-targeted ubiquitin ligases) were identified as a new 
type of monomeric RING E3 ligase (Perry et al., 2008).  STUbls contain two N-terminal 
SUMO-interactions motifs (SIMs) which are required for recognition and ubiquitination 
of its SUMOylated target proteins.  Many RING E3 ligases are part of larger complexes 
where target protein recognition is mediated by a different subunit of the complex.  
Cullin-RING E3 ligases (CRLs) form complexes with different substrate binding proteins 
such as the F box, SOCS box, and BTB domain-containing proteins (Petroski and 
Deshaies, 2005).  These substrate binding proteins often contain WD40 repeats, leucine 
rich repeats, or ankyrin repeats to mediate the interaction with target proteins.   
HECT E3 ligases 
The HECT domain is C-terminal domain of ~350 residues.  This domain was first 
described in E6AP, a E3 ligase hijacked by the human papillomavirus (HPV) E6 protein 
to mediate degradation of p53 (Scheffner et al., 1993).  E6AP was the first E3 to be 
purified and when used in an in vitro assay, it was shown to form a thioester with Ub 
before transferring it to p53.  Sequence analysis revealed several protein sequences with 
C-terminal residues similar to E6AP that were also capable of thioester formation 
(Huibregtse et al., 1995).  E6AP and these related proteins were classified as a new group 
of Ub E3 ligases, the HECT E3s.   
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The first crystal structure of a HECT E3 was of the HECT domain of E6AP 
bound to the E2 enzyme, UbcH7 (Huang et al., 1999).  This U-shaped structure revealed 
a bilobal HECT domain with the N-terminal lobe mediating E2 binding and a C-terminal 
lobe containing the catalytic cysteine for thioester formation.  Interestingly, the catalytic 
cysteines on UbcH7 and the C-lobe of E6AP were found to be separated by 41 Å (Figure 
1.2).  This distance was much greater than the 2.5Å required for transthiolation and it was 
proposed that transfer of Ub from E2 to E3 would require a large conformational change 
of the HECT domain.  Subsequent crystal structures of HECT domains (WWP1, 
SMURF2, HUWE1, NEDD4L) revealed different orientations of the N- and C-lobes 
(Kamadurai et al., 2009; Ogunjimi et al., 2005; Pandya et al., 2010; Verdecia et al., 
2003).  An L-shape, similar to that of HECTE6AP, was observed for the HECTSMURF2, 
while an inverted T shape was observed for HECTHUWE1, HECTNEDD4L, and HECTWWP1.  
The shift of the C-lobe to the middle of the N-lobe placed the E2 and E3 cysteines much 
closer; in the case of HECTNEDD4L and UbcH5B, only 8Å apart.    
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Figure 1.2: E2-HECT domain structures 
The crystal structures for UbcH7-HECTE6AP (left) and UbcH5B-HECTNEDD4L (right) 
indicate the C lobe of the HECT domain is very flexible.  The E2 is displayed in red, N-
lobe in dark blue, C-lobe in light blue, and ubiquitin in purple (NEDD4L structure only).  
The distance between the catalytic cysteines is indicated by the yellow line.  Structures 
were created using PyMol and the PDB files 1DF5 and 3JW0.    
      
While the C-terminal HECT domain is the catalytic domain of the E3, the N-
terminal regions of HECT E3s mediate target protein recognition.  For example, the 
Nedd4 family of HECT E3 ligases has WW domains which interact with PPXY (Pro-Pro-
X-Tyr) motifs found in their target proteins.  The HPV E6 protein binds E6AP at a 17 
amino acid peptide approximately 100 residues upstream of the HECT domain.  N-
terminal RCC1-like domains (RLDs), known to mediate protein-protein interactions, 
distinguish the Herc family of HECT E3 ligases (discussed in more detail below).   
HECT E3 ligases are a major focus of our lab and currently we are interested in 
the mechanism by which HECT E3 ligases control the type of linkage formed between 
molecules of Ub.  E6AP preferentially catalyzes K48-linked chains, while Rsp5, a S. 
cerevisiae HECT E3, preferentially synthesizes K63-linked chains.  Our lab recently 
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determined that chain type specificity among HECT E3 ligases is a function of the C lobe 
of the HECT domain (Kim and Huibregtse, 2009).  Kim et al. showed that exchanging 
the C lobe of the K63-specific HECT E3 Rsp5 for the C lobe of the K48-specific HECT 
E3 E6AP resulted in Rsp5 preferentially catalyzing K48-linked chains.  In addition to 
chain type specificity, our lab is also interested Ub chain elongation.  The sequential-
addition model of polyubiquitination proposes a single Ub molecule is added to the 
substrate and then the chain is elongated by conjugation of additional Ub monomers.  
One problem with this model is accounting for the formation of long chains composed of 
up to 30 Ub molecules.  Recently, a non-covalent ubiquitin binding domain (UBD) was 
discovered on the N-lobe of the HECT domains for RSP5 and SMURF1 (French et al., 
2009; Ogunjimi et al.).  Mutational analysis of the SMURF1 UBD found a decrease in 
polyubiquitination of SMURF1 itself as well as the substrate Rho.  Ogunjimi et al 
proposed a role for the N-lobe UBD in stabilizing and positioning Ub at the growing end 
of the chain for addition of another molecule of Ub.  We are in the process of 
characterizing the role of the N-lobe UBD in polyubiquitination with other HECT E3s 
such as RSP5 and E6AP.       
1.2 ISG15: UBIQUITIN-LIKE PROTEIN 
Ubiquitin-like proteins (Ubls) are proteins that structurally resemble the β-grasp 
fold of Ub and contain a C-terminal glycine required for isopeptide bond formation with 
target proteins (Figure 1.3).  To date, seventeen human Ubls have been identified, 
including Nedd8, FAT10, SUMO1-4, and ISG15 (Schulman and Harper, 2009).  Ubls are 
conjugated to cellular proteins via an enzymatic cascade similar to that of Ub.  Ubls also 
have specific Ubl-specific proteases (ULPs) which cleave the C-terminus to process the 
Ubl before conjugation as well as hydrolyze Ubls from target proteins.  With the 
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exception of SUMO2/3 and Nedd8, Ubls have not been found to form poly-Ubl chains 
(Jones et al., 2008; Vertegaal, 2010).   
While the Ub system has 60 E2s and over 600 E3s, no more than two E2s and at 
most a few E3s have been identified for any Ubl (Kerscher et al., 2006).  Until recently, it 
was thought that each Ubl had dedicated E1, E2, and E3 enzymes and therefore Ubl 
pathways were considered to be parallel, but distinct from the Ub pathway.  This 
paradigm has been challenged with the discovery of new pathway enzymes.  For 
example, a newly discovered E1 for Ub, Uba6, has been reported to be the E1 for FAT10 
as well (Chiu et al., 2007).  In addition, two structurally-distinct Ubls involved in 
autophagy, Atg8 and Atg12, are activated by a single E1 (Ichimura et al., 2000; 
Mizushima et al., 1998).   
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Figure 1.3: Ubiquitin-like proteins structurally resemble ubiquitin.   
Nedd8 (green) and ISG15 (red) structurally resemble ubiquitin (blue).  Structures created 
with Pymol using the PDB files 1Z2M, 2KO3, and 1UBQ. 
1.2.1 Nedd8 
Nedd8 (neural precursor cell expressed, developmentally down-regulated 8) is the 
most similar of all Ubls to Ub and is highly conserved in most eukaryotes.  Model 
organisms such as Schizosaccharomyces pombe, Caenorhabditis elegans, Drosophila, 
Arabidopsis, and mouse require Neddylation for viability with the exception of S. 
cervisiae (Rabut and Peter, 2008).  Analysis of mouse embryos deficient in Neddylation 
revealed an essential role for Nedd8 in cell cycle progression (Tateishi et al., 2001).  The 
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primary targets of Nedd8 appear to be cullin-RING E3 Ub ligases (CRLs), although 
targets not related to CRLs exist as well (Jones et al., 2008).  Nedd8 modification of the 
cullin subunit of CRLs induces a conformational change that activates the Ub E3 ligase 
(Duda et al., 2008).  At the same time, this modification prevents the cullin inhibitor, 
CAND1, from binding CRLs.  The fact that many substrates of CRLs are involved in cell 
cycle control corresponds with the role of Nedd8 in cell cycle progression.   
Despite its similarity to Ub, there is no apparent cross-reactivity of Nedd8 with 
enzymes of the Ub system.  The features of the Nedd8 E1 that confer specificity for 
Nedd8 have been identified.  Nedd8 E1 specifically charges Nedd8 due to a unique Arg 
present in the Nedd8 E1 that repels Arg72 of Ub, but accepts Ala72 of Nedd8 (Souphron 
et al., 2008).  The specificity of the Nedd8 E2 is dictated by its interaction with the E1 
rather than Nedd8.  The ubiquitin-fold domain of the Nedd8 E1 recruits the E2 through 
interactions with the E2 α1-helix and the β1-β2 loop (Huang et al., 2005).  In addition, 
the Nedd8 E2 contains a unique N-terminal extension that interacts specifically with a 
unique groove in the adenylation domain of the Nedd8 E1 (Huang et al., 2004).  The 
identity of a Nedd8 specific E3 enzyme is unclear.  While Dcn1 has been reported to act 
as a scaffold-type E3 ligase for the modification of CRLs, the Nedd8 E2s have also been 
reported to interact directly with the RING domain of CRLs in order to mediate cullin 
Neddylation (Huang et al., 2009; Kurz et al., 2008). 
1.2.2 SUMO 
SUMO (small ubiquitin-related modifier) proteins share little amino-acid identity 
with Ub, but maintain a similar structure (Bayer et al., 1998).  Organisms such as S. 
cervisiae and C. elegans have only one SUMO protein compared to the four found in 
humans.   Like Nedd8, most organisms require SUMOylation for viability (Geiss-
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Friedlander and Melchior, 2007).  While SUMO is known to function in many cellular 
processes including DNA repair, RNA metabolism, and mitochondrial activity, 
SUMOylation is frequently associated with regulation of transcription.  In addition, many 
of the SUMO target proteins identified to date are transcription factors (TFs).  
Interestingly, several studies found SUMOylated TFs were maximally repressed despite 
the fact that only a small fraction of the TF was modified (Hay, 2005).  One model 
suggests this is a result of short-term modification: SUMOylation is required to recruit a 
repressor complex which, once bound, allows deSUMOylting enzymes to remove SUMO 
without altering the bound complex thus continuing repression.             
A unique aspect of the SUMO pathway involves the recognition of target 
proteins.  Ubc9, the E2 for SUMO, is capable of directly interacting with and modifying 
target proteins containing the consensus motif Φ-K-x-E/D (Φ is a hydrophobic, K is the 
lysine attached to SUMO, x is any amino acid, and E or D is an acidic residue) (Bernier-
Villamor et al., 2002).   While several E3 ligases exist for SUMO, reports suggest they 
function non-enzymatically to enhance SUMO conjugation or confer additional 
specificity in target recognition.  For example, Siz/PIAS-RING (SP-RING) E3 ligases 
enhance and redirect SUMOylation via their PINIT domain.  Structural and mutational 
analysis showed the PINIT domain of Siz1 is required to position a non-consensus lysine 
residue in PCNA for SUMOylation by Ubc9 (Yunus and Lima, 2009).  SUMOylation of 
PCNA at this lysine residue has been proposed to inhibit recombination repair events 
(Papouli et al., 2005; Pfander et al., 2005).               
1.2.3 Characteristics of ISG15   
ISG15 was the first Ubl identified (Figure 1.4) (Farrell et al., 1979).  ISG15 is a 
17 kDa protein resembling two molecules of Ub connected by a linker of six amino acids 
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(Narasimhan et al., 2005).  There are several unique features of ISG15 relative to other 
Ubls.  First, and most importantly, ISG15 is transcriptionally induced by type I 
interferons (IFN-α/β) and is therefore conjugated to proteins only in the context of a viral 
or microbial infection.  Second, ISG15 is found only in vertebrates.  Third, ISG15 is not 
well conserved between species compared to Ub and other Ubls.  Human ISG15 is only 
65% identical to mouse ISG15, whereas Ub is 100% identical between human and 
mouse; mouse and rat ISG15 are 73% identical.  Finally, ISG15 is the only Ubl where the 
last six residues of the protein (LRLRGG) are identical to that of Ub.  These residues are 
important for E1Ub discrimination between Ub and other Ubls and the identity suggested 
potential overlap between the ISG15 and Ub pathways.  
 
 
Figure 1.4: Timeline of important discoveries in the ISG15 field.   
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1.2.4 The ISG15 pathway enzymes 
Although ISG15 was first identified as a Ubl in 1992, it was not until 2001 that 
the first enzyme involved in its conjugation was identified (Loeb and Haas, 1992; Yuan 
and Krug, 2001).  Using 32P-labeled ISG15 and IFN-treated A549 cell lysates, the Krug 
lab identified Ube1L as the ISG15 E1.  Ube1L is the most similar human E1 enzyme 
compared to E1Ub (62% similar).  Unlike other Ub/Ubl E1 enzymes, Ube1L is the only 
E1 transcriptionally induced by IFN-α/β (Kim et al., 2004; Yuan and Krug, 2001).  
Crystal structures of the E1s for Nedd8, SUMO, and Ub reveal three common domains: 
an adenylation domain, a catalytic-cysteine-containing domain, and a C-terminal Ub-fold 
domain (UFD).  The UFD of E1s for Nedd8, SUMO, and Ub have been shown to be 
important in the recruitment of their respective E2s (Figure 1.5) (Huang et al., 2005; Lee 
and Schindelin, 2008; Lois and Lima, 2005).  Based on structural propensities of residues 
conserved with Uba3, Ube1L is also predicted to contain a C-terminal UFD as well. 
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Figure 1.5: Crystal structure of the interaction of Nedd8’s E2 (Ubc12core) with the 
ubiquitin-fold domain of the Nedd8 E1 (NE1UFD).   
NE1UFD is in light blue while Ubc12core is in green.  NE1UFD has two grooves: one holds 
the α1 helix and the other holds the β1-β2 loop of Ubc12core.  Ubc12core is missing a 26 
residue N-terminal extension which interacts with a unique groove in the NE1 
adenylation domain.  Structure created with PyMol using the PDB file 1Y8X.   
 
Following identification of Ube1L, the Krug and Huibregtse labs used 
recombinant purified ISG15 to isolate the ISG15 E2, UbcH8 from IFN-β-treated A549 
cells (Zhao et al., 2004).  A previous study had shown UbcH8 was transcriptionally 
induced by IFN-α (Nyman et al., 2000) and Zhao et al. confirmed UbcH8 mRNA 
induction following IFN-β treatment.  UbcH8 had been reported in several cases to 
function in Ub conjugation pathways (Chin et al., 2002; Urano et al., 2002; Wheeler et 
al., 2002; Zhang et al., 2000).  In addition, many studies reported UbcH8 to function in a 
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manner that was redundant with UbcH7 (Fortier and Kornbluth, 2006; Imai et al., 2000; 
Moynihan et al., 1999; Shimura et al., 2000), suggesting that UbcH8 might function in 
both the Ub and ISG15 conjugation systems.  UbcH7 is the most closely related E2 (55% 
identity, 72% similarity to UbcH8) and recent phylogenetic analysis of E2 enzymes 
grouped UbcH7 and UbcH8 into their own family (Michelle et al., 2009).  Despite the 
similarity, depletion of UbcH8 by siRNAs eliminated virtually all ISG15 conjugation in 
IFN-β-treated cells, whereas depletion of UbcH7 had no effect on ISG15 conjugation 
(Zhao et al., 2004).  These results strongly suggested that UbcH8 is the only E2 enzyme 
for the ISG15 pathway, however given the functional redundancy of E2s in the Ub 
system it was difficult to unambiguously determine whether UbcH8 functions in Ub 
conjugation in vivo. 
Herc5 was identified as the major E3 for ISG15 by the Huibregtse and Krug labs 
(Dastur et al., 2006).  The enzymes for Ub/Ubl conjugation pathways often undergo auto-
conjugation, a process in which the enzyme transfers Ub/Ubl to itself.  As a result, these 
components are often identified in the process of identifying target proteins by mass 
spectrometry.  Consistent with this, proteomic analysis to find ISG15 target proteins 
identified the ISG15 enzymes Ube1L and UbcH8 (Zhao et al., 2005).  Interestingly, a 
single HECT E3 ligase, Herc5, was also identified.  In addition, microarray analysis of 
IFN-β treated HeLa cells showed that like ISG15, Ube1L, and UbcH8, the expression of 
Herc5 is transcriptionally induced by IFN-β.  These results suggested that Herc5 might be 
an E3 ligase for the ISG15 conjugation pathway.  Dastur et al. showed that depletion of 
Herc5 by siRNA eliminated nearly all ISG15 conjugation to target proteins in IFN-β 
treated cells.  Furthermore, ISGylation could be reconstituted by co-transfection of 
Ube1L, UbcH8, ISG15, and Herc5 in non-interferon treated cells.   
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The microarray analysis identified several other IFN-induced E3 ligases in 
addition to Herc5, including TRIM25 and Herc6 (Dastur et al., 2006).  TRIM25 (Efp) is 
known to act as a Ub RING E3 ligase for 14-3-3σ, a negative regulator of the cell cycle.  
One report showed that TRIM25 could auto-conjugate with ISG15 (although not as well 
as with Ub), while another report stated TRIM25 could transfer ISG15 to 14-3-
3σ.(Nakasato et al., 2006; Zou and Zhang, 2006)  Our lab found that depletion of 
TRIM25 by siRNA had no effect on ISG15 conjugation, nor did the transfection of 
plasmids expressing E1, E2, ISG15, and TRIM25 reconstitute ISG15 conjugation 
(Dastur, 2007).  Herc6, a HECT E3 ligase, is 50% identical to Herc5 and has a very 
similar domain organization.  Similar to TRIM25, depletion of Herc6 by siRNA or 
addition of Herc6 by plasmid transfection had no effect on ISG15 conjugation (Dastur et 
al., 2006; Dastur, 2007).  It is unclear what, if any, role exists for human Herc6 in ISG15 
conjugation. 
Interestingly, human Herc5 does not have a direct equivalent in mice or rats.  
However, the human Herc5 and Herc6 genes are adjacent to each other on chromosome 4 
and are very likely related to each other through a gene duplication event (Hochrainer et 
al., 2005).  As stated previously, both genes are transcriptionally regulated by interferon 
signaling and the human Herc5 and Herc6 proteins are 50% identical with very similar 
domain organizations.  Mouse Herc6 is also interferon-induced and located at the 
corresponding genomic position as human Herc6. While it was proposed that Herc5 was 
the result of a gene duplication of Herc6 in the primate lineage, this is likely incorrect 
since other mammals (dogs, cows, sheep, monkeys) have both the Herc5 and Herc6 genes 
in a similar arrangement as in the human genome, suggesting that Herc5 was lost in the 
evolution of the rodent lineage.  Although there is no evidence that human Herc6 plays a 
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significant role in ISG15 conjugation, it is conceivable that mouse Herc6 plays the 
equivalent role to human Herc5 in conjugation of mouse ISG15.  In support of this 
hypothesis, Versteeg et al. found that ISGylation could be reconstituted by transfection of 
mUbe1L, mUbc8, mISG15, and mHerc6 (Versteeg et al., 2010).  Conjugation was 
dependent on all four components as well as the active-site cysteine present in the HECT 
domain of mHerc6.   
Deconjugating enzymes function in Ub precursor cleavage, recycling of Ub, 
editing of Ub chain topology, and rescuing of proteins from the proteasome.  Like Ub, 
ISG15 is expressed as an inactive precursor and it must be cleaved to expose a Gly-Gly 
motif at the C-terminus.  Unlike Ub, there is no evidence that ISGylated proteins are sent 
to the proteasome or that poly-ISG15 chains are formed.  The first Ubl-specific protease 
(ULP) identified for ISG15 was Ubp43 (Usp18 in humans) (Malakhov et al., 2002).  
While Ubp43 is considered an ISG15 deconjugating enzyme, it is not required for 
precursor processing of ISG15, as ISG15 conjugates still accumulate in Ubp43 -/- mice.  
In addition, mice lacking Ubp43 have a severe phenotype characterized by 
hydrocephalus, premature death, and neurological symptoms that can not be rescued by 
the simultaneous knockout of ISG15 and Ubp43 (Knobeloch et al., 2005; Ritchie et al., 
2002).  These results suggest ISG15-independent or enzymatic-independent functions 
exist for Ubp43.  To date, two enzymatic-independent functions have been found for 
Ubp43: 1) Ubp43 negatively regulates IFN-α/β signaling by competing with Janus 
activated kinase (JAK) for binding to IFNAR2 and 2) Ubp43 limits apoptosis in IFN-α-
treated cells (Malakhova et al., 2006; Potu et al., 2010).  Since Ubp43 is not required to 
process the inactive ISG15 precursor, other ULPs must exist for ISG15.  Recently, a 
screen for ISG15 ULP’s identified Usp2, Usp5, Usp13, and Usp14, in addition to Ubp43 
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(Catic et al., 2007).  It is not known whether any of these newly identified ULPs can 
cleave the C-terminal region of the precursor ISG15 or remove ISG15 from target 
proteins.   
1.2.5 The di-ubiquitin like structure of ISG15 
Sequence alignment of Ub with the N-terminal and C-terminal domains shows 
32% and 37% identity, respectively.  The two ubiquitin-like domains are connected by a 
six residue linker and contact each other via van der Waals interactions between N-
terminal histidine 39 and phenylalanine 41 and the C-terminal proline 136 and glycine 
138 (Narasimhan et al., 2005).  Mutation of either the N-terminal or C-terminal contact 
sites reduces conjugation in vivo, although the C-terminal mutations have a larger effect 
on conjugation (Appendix I).  It is possible that the C-terminal contact sites have a 
function in addition to stabilization such as E1 activation.  While the C-terminal domain 
of ISG15, including the terminal Gly-Gly motif, is clearly required for substrate 
conjugation, the role of the N-terminal domain is unclear.  Chang et al. reported deletion 
of the N-terminal domain of ISG15 (ISG15-∆N) did not inhibit activation by Ube1L or 
transfer to UbcH8 in vitro, but did impair overall conjugation when transfected with 
Ube1L and UbcH8 in vivo (Chang et al., 2008).  In contrast, in our hands, overall 
conjugation did not appear to be decreased when ISG15-∆N was co-transfected with 
Ube1L, UbcH8, and Herc5 (Appendix I).  Conclusions regarding the contact site mutants 
or the N-terminal domain of ISG15 can not be made without careful kinetic analyses of 
these mutants at each step of conjugation.  In this regard, it is important to note that while 
Ube1L and UbcH8 activation has been analyzed in vitro, conjugation of ISG15 target 
proteins has not been fully reconstituted.    
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1.2.6 Identification of ISG15 target proteins 
More than 300 cellular proteins have been identified as target proteins by three 
proteomics studies (Giannakopoulos et al., 2005; Wong et al., 2006; Zhao et al., 2005).  
The first study, by the Krug and Huibregtse labs, identified 158 high-confidence target 
proteins.  Zhao et al. expressed a double-tagged ISG15 protein (6XHis and FLAG N-
terminal tags), along with Ube1L and UbcH8, in HeLa cells, and then treated the 
transfected cells with IFN-β.  Extracts were prepared 24 hours before preparation for 
mass spectrometry.  In a second study, Giannakopolous et al. identified ISG15 conjugates 
in interferon-treated human cells (U937 cells) and in mouse Ubp43-null MEFs using an 
antibody recognizing endogenously expressed ISG15.  Mass spectrometry identified a 
total of 76 mouse and human proteins in the immunoprecipitates.  Finally, Wong et al. 
identified 174 target proteins using stably expressed FLAG-ISG15 in A549 cells were 
treated with IFN-β for 48 hours.  Together, these three studies identified 312 unique 
proteins as potential ISG15 target proteins. 
The identification of ISG15 target proteins was highly anticipated, as it was hoped 
that this would provide valuable insight into the biologic function of ISG15.  This, for 
example, was the case for identification of targets of Sumo, where target identification 
revealed a very high percentage of targets to be nuclear proteins involved in regulation of 
DNA- and RNA-related processes.  Unfortunately, the identification of ISG15 target 
proteins was, at least initially, not particularly revealing.  The targets were largely 
abundant constitutively expressed proteins, with the exception of approximately 15 
targets that were themselves interferon-induced proteins.  The interferon-induced targets 
included some of the better-characterized antiviral ISGs, including PKR, MxA, RIG-I, 
p56, and STAT1 (discussed further below).  The constitutively expressed proteins 
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encompassed both cytoplasmic and nuclear proteins involved in a diverse array of 
cellular functions, including cytoskeletal organization, stress responses, translation, 
transcription, RNA splicing, and general metabolism.  A prediction of the biological 
function for ISG15 could not be inferred from the diverse set of target proteins.  
Furthermore, the fraction of an ISGylated protein is often no more than 10-20% of the 
total pool of the target protein examined (Zhao et al., 2005).  This low level of 
modification is an additional complication in predicting a function for ISG15.  
1.2.7 Recognition of ISG15 target proteins 
Ub E3 ligases function to transfer Ub to specific substrates, so it is no surprise 
that more than 600 human genes encoding putative Ub E3 ligases have been identified.  
Generally, the recognition of target proteins by E3 ligases is mediated through protein-
protein interaction motifs found in both sets of proteins, but no common primary 
sequence motif has been identified in ISG15 target proteins.  Herc HECT E3 ligases 
possess N-terminal regulator of chromosome condensation 1 (RCC1)-like domains 
(RLDs) known to mediate protein-protein interactions (Hadjebi et al., 2008).  RCC 
repeats were first identified in the RCC1 protein, a guanine nucleotide exchange factor.  
RCC1 contains seven RCC repeats which form a seven-bladed β-propeller structure 
which binds Ran on one face and chromatin on the other.  The RLD of Herc5 consists of 
three less conserved RCC repeats (residues 1-150) followed by four canonical RCC 
repeats between residues 151-350 (Hadjebi et al., 2008).  Herc5 mutants lacking either 
the entire RLD or the first two RCC repeats cannot support target protein ISGylation 
however, both mutants are able to conjugate ISG15 to themselves (auto-conjugation).  
The role of the Herc5 RLD in target protein recognition will be discussed in more detail 
in Chapter 4.     
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1.2.8 The effects of ISGylation on target protein function 
Only modest progress has been made on determining the functional implications 
of ISG15 conjugation.  Currently, there are a number of cell-based approaches that can be 
used to generate ISGylated proteins and validate modification of individual proteins.  
However, it is important to note that an in vitro ISGylation system has not yet been 
established.  Without such a system, it is not possible to easily generate purified 
ISGylated target proteins for biochemical analyses.  There are two broad possibilities for 
the biochemical function of ISGylated target proteins: 1) ISG15 is a specific signaling 
molecule (in the manner that Ub signals to the proteasome), or 2) ISG15 non-specifically 
disrupts the function of its target proteins by physical occlusion or obstruction.  There is 
little or no evidence in support of the first idea, however there are a few studies discussed 
below which provide support for the second idea.  One major issue with these studies is 
only a very small fraction of the total pool of any target protein is modified with ISG15 
and therefore, it is hard to imagine that overall protein function would be disrupted 
(discussed further in Chapter 6).    The targets described below are Ubc13, PP2Cβ, and 
filamin B. 
Ubc13 is a ubiquitin E2 enzyme that functions in the generation of K63-linked 
polyubiquitin chains.  Two reports showed that Ubc13 is ISGylated at lysine residue K92, 
which lies near the active-site cysteine residue of the protein (C87) (Takeuchi and 
Yokosawa, 2005; Zou et al., 2005).  Both studies showed that the ISGylated form of 
Ubc13 was defective for ubiquitin thioester formation.  Given the proximity of the C87 to 
K92 in the structure, the inhibition of thioester formation is likely to be simply a result of 
steric occlusion of C87 by the conjugated ISG15 molecule.  The downstream effects of 
this inhibition have been suggested to result in prevention of NF-κB activation, as K63-
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linked polyubiquitination catalyzed by the Ubc13/Mms2 complex is a critical component 
of the signaling pathway that leads to NF-κB activation.  NF-κΒ activation, in turn, is 
critical for transcriptional activation of genes involved in the innate immune response, 
including IFN-β.   An unresolved problem with this proposed mechanism is that only a 
small fraction of Ubc13 is ISGylated, and it is not clear how this would lead to a 
significant inhibition of overall Ubc13 activity. 
PP2Cβ is a protein phosphatase that dephosphorylates the TAK1 and IKK 
kinases, leading to inhibition of NF-κΒ signaling.  Using a NFκΒ luciferase reporter 
assay, it was shown that ISGylation of PP2Cβ inhibited its activity and lead to a slight 
increase in luciferase activity (Takeuchi et al., 2006).    Similar to Ubc13, only a small 
fraction of PP2Cβ is ISGylated and it is unknown what effect the resulting changes in 
NF-κΒ activation would have in the context of a viral infection.   
Filamin B is one of three related actin binding proteins that are critical for 
crosslinking of cortical actin filaments.  At early time points after interferon stimulation, 
filamin B tethers RAC1 and a MAP kinase module, which promotes activation of JNK 
and JNK-mediated apopotosis.  The ISGylation of filamin B was shown to lead to release 
of RAC1, MEKK1, and MKK4 from the scaffold, preventing JNK activation (Jeon et al., 
2008).  A model was proposed whereby ISGylation of filamin B, at relatively late time 
points after interferon stimulation, leads to the eventual inactivation of JNK. 
1.3 ISG15: ANTI-VIRAL PROTEIN. 
1.3.1 The innate immune system 
When cells are infected by bacteria or viruses, the innate immune system is first 
to detect pathogens using pattern recognition receptor proteins (PRRs) (Mogensen, 2009).  
PRRs can quickly detect pathogen-associated molecular patterns (PAMPs) present on 
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bacteria or viruses.  Recognition of pathogens via PRRs triggers the recruitment of 
adaptor molecules and the activation of multiple signaling cascades involving NF-κβ, 
mitogen-activated protein kinases (MAPKs), and interferon-regulatory factors (IRFs).  
Ultimately, pro-inflammatory cytokines and type I interferons, also known as IFN-α and 
IFN-β (IFN−α/β), are produced (Figure 1.6).  IFN-α/β is then secreted where it can bind 
IFN-α/β receptors on uninfected cells nearby, as well as the initially infected cell, 
resulting in transcription over a hundred of interferon stimulated genes (ISGs) and the 
formation of an anti-viral state in the uninfected cells (Figure 1.7).  ISG15 (interferon-
stimulated gene of 15 kDa) is one of the most strongly induced ISGs (Birmachu et al., 
2007; Blomstrom et al., 1986; Der et al., 1998). 
Virus recognition by PRRs 
Toll-like receptors (TLRs) are the most extensively studied PRRs.   TLRs are a 
family of membrane proteins which, upon recognition of PAMPs, dimerize and undergo 
conformational changes that allow them to recruit adaptor proteins such as MyD88 and/or 
TRIF to mediate signal transduction (Mogensen, 2009; Trinchieri and Sher, 2007).  Viral 
glycoproteins are recognized by TLR2 and TLR4 on the cell surface, while viral RNA or 
DNA is recognized by TLRs localized at the endosome.  Each of the endosomal TLRs is 
specific for a type of viral nucleic acid: TLR3 for dsRNA, TLR7/8 for ssRNA, and TLR9 
for CpG DNA.  Some cell types express only a subset of the TLRs described.  For 
example, plasmacytoid dendritic cells (pDCs) express TLR7 and TLR9.  With the 
exception of TLR2, the TLRs recognizing viruses trigger both pro-inflammatory 
cytokines and type I interferons.  The MyD88-dependent pathway, utilized by all TLRs 
except TLR3, is responsible for the activation of NF-κβ and AP-1.  Additionally, TLR7/8 
and TLR9 trigger a MyD88-dependent pathway that leads to IRF7 activation.  TRIF-
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dependent signaling, used by TLR3 and TLR4, can mediate the activation of all four 
transcription factors: NF-κβ, AP-1, IRF3, and IRF7.   
 
 
Figure 1.6: Activation of the innate immune response by viruses.   
Pattern recognition receptor proteins (PRRs) are activated by viral pathogen-associated 
molecular patterns (PAMPs) leading to the induction of type I interferons and pro-
inflammatory cytokines.  Adapted from Gillet et al. 2008, Trinchieri and Sher 2007, and 
Fensterl and Sen 2009. 
RIG-I like receptors (RLRs), including RIG-I (retinoic acid-inducible gene I), 
Mda5 (melanoma differentiation-associated gene 5), and LGP2 (laboratory of genetics 
and physiology 2), are characterized by a DExD/H-box RNA helicase domain and 
contain a C-terminal regulatory domain for RNA binding.  While RLRs such as RIG-I 
and Mda5 possess CARD (caspase recruitment) domains to initiate downstream 
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signaling, LGP2 does not and a recent study suggests it assists RIG-I and Mda5 with viral 
RNA recognition rather than mediating a response on its own (Satoh et al.).  RLRs sense 
specific viruses and appear to have preferential ligands: RIG-I recognizes short dsRNAs 
and 5’ triphosphate RNA, while Mda5 recognizes long dsRNAs (Kato et al., 2008; Kato 
et al., 2006).  Viral dsRNA is also recognized by protein kinase R (PKR) however, RLRs 
appear to be the major contributors to dsRNA-activated responses.  Like the TLRs, 
activation of the RLRs and PKR by viral RNA ultimately leads to the production of 
cytokines and type I interferons. While it is clear that RLRs with CARD domains interact 
with the adaptor protein MAVS (also known as IPS-1, CARDIF, or VISA) to mediate 
these responses, it is unclear if PKR assists RIG-I and Mda5 like LGP2 or if it 
independently leads to induction of cytokines and type I interferons. 
Cytosolic DNA can trigger type I interferons independently of TLR9 and studies 
have identified the cytoplasmic DNA sensors, DAI (DNA dependent activator of IRFs) 
and AIM2 (absent in melanoma 2) (Schroder et al., 2009; Takaoka et al., 2007).  While 
AIM2 does not induce IFNs, results suggest DAI interacts with IRF3 to mediate IFN 
induction.  Alternative sensors for pathogenic DNA recognition have been proposed as 
knockdown of DAI had little effect on IFN induction.  Recently, a new mechanism for 
cytosolic DNA recognition has been identified.  RNA polymerase III has been shown to 
transcribe dsDNA into dsRNA which is then capable of activating RIG-I (Ablasser et al., 
2009; Chiu et al., 2009).   
PRRs and type I interferons 
As discussed above, recognition of pathogens via PRRs triggers multiple 
signaling cascades which result in the activation of the transcription factors NF-κβ, AP-1 
(via MAPKs), interferon-regulator factor-3, and -7 (IRF3 and IRF7).  NF-κβ regulates 
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the induction of pro-inflammatory cytokines with the help of AP-1, while IRF3 and IRF7 
are the key regulators of the type I interferon response.  IFN-α is only induced by 
homodimers of IRF7, but homodimers of IRF3 or heterodimers of IRF3 and IRF7 can 
induce IFN-β.  IFN-β is most stably induced by a complex known as the enhanceosome.  
This complex is formed when IRF3 and/or IRF7 form a complex with AP-1, NF-κβ, and 
the co-activator CBP or p300 (Honda and Taniguchi, 2006). 
The induction of type I interferons is biphasic and results in a positive feedback 
loop that strengthens the interferon response (Haller et al., 2006).  During the early phase, 
IFN-β is induced and secreted in an autocrine and paracrine manner.  This leads to the 
upregulation of IRF7 and results in the late phase induction of IFN-α and the continued 
production of IFN-β.  Originally it was thought that the early phase induction of IFN-β 
was entirely dependent on homodimers of IRF3 because IRF3 is constitutively expressed, 
while IRF7 is expressed at very low levels (in all cells except for pDCs).  However, both 
mice lacking IRF3 and mice lacking IRF7 showed very reduced levels of IFN-
β indicating IRF7 plays a role in the early phase induction of IFN-β (Honda et al., 2005). 
The anti-viral response of interferons 
Interferons (IFNs) are secreted cytokines with anti-viral activity (Samuel, 2001).  
Type I IFNs include IFN α, β, ε, κ, and ω, however IFN α and β are the major members.  
Type I IFNs can be produced by all cell types and function to directly inhibit viral 
activity.  IFN-γ is the sole member of Type II IFNs.  It is primarily produced by T cells 
and NK cells and acts on macrophages to upregulate MHC molecules.  The most recently 
discovered group of IFNs, Type III IFNs, are composed of three IFN-λ molecules (Ank 
and Paludan, 2009).   Type III IFNs are induced by IRF3 and IRF7 and function similarly 
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to Type I IFNs, however they are limited to primarily to epithelial cells (Ank et al., 2008; 
Sommereyns et al., 2008).   
Each type of interferon has its own heterodimeric receptor.  IFNAR1/2 and 
IFNAG1/2 are the receptors for IFN-α/β and IFN-γ, respectively, and are ubiquitously 
expressed (Samuel, 2001).  In contrast, The IFN-λ receptor is composed of IL-10Rβ and 
the cell-type specific IFNλR1 limiting this receptor to epithelial cells primarily (Ank and 
Paludan, 2009).  Regardless of the type of interferon, the binding of the ligand to the 
receptor activates the JAK-STAT signaling pathway.  Janus activated kinases (JAKS) are 
recruited to the receptor and activate themselves via autophosphorylation.  In addition, 
JAKS phosphorylate the IFN receptor and members of the signal and activator of 
transcription (STAT) family of proteins.  Phosphorylated STAT proteins dimerize and 
can form complexes with other proteins before translocation into the nucleus and binding 
of specific DNA sequences within the promoters of interferon stimulated genes (ISGs).  
Type II IFN induces a STAT1 homodimer which binds GAS (gamma activated 
sequences) elements of IFN-γ target genes.  Type I IFN induces the formation of a 
complex known as the interferon stimulated gene factor 3 complex (ISGF3).  This 
complex is composed of a STAT1/STAT2 heterodimer bound to IRF9.  IFN-α/β 
inducible genes are transcribed following the binding of ISGF3 to promoters containing 
interferon stimulated response elements (ISREs).  
Mice lacking the IFN-α/β receptor are susceptible to numerous viruses indicating 
the requirement of IFN-α/β and the transcription of ISGs for an effective response 
against viral infection (Muller et al., 1994; Ryman et al., 2000).  These hundreds of ISGs 
are able to mount an anti-viral response via many different mechanisms.  For example, 
MxA is known to accumulate at the ER membrane where it can detect and trap viral 
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nucleocapsid-like structures  (Haller et al., 2007).  Cellular and viral translation is 
inhibited through the action of several different proteins: activated PKR phosphorylates 
EIF2α (Dar et al., 2005), while human p56 and p54 inhibit translation through the 
binding of eIF3 (Terenzi et al., 2006).  The 2’-5’ OAS-RNaseL pathway functions to 
degrade viral RNA (Hovanessian and Justesen, 2007).  Viral dsRNA activates 2’-5’ OAS 
which in turn activates RNaseL.  The RNA degraded by RNaseL can also activate the 
RLRs RIG-I and Mda5 (Malathi et al., 2007).  ISG15 is a highly induced ISG, however 
the mechanism behind its role in the anti-viral response is unclear and will be discussed 
in more detail in Chapter 5.    
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Figure 1.7: Innate immune response to viruses 
Viral recognition by the innate immune system results in the production of pro-inflammatory 
cytokines and a biphasic induction of type I interferons.  During the early phase, IFN-β is induced 
and secreted where it can then bind to the initially infected cell as well as neighboring cells.  This 
leads to the upregulation of IRF7 and results in the late phase induction of IFN-α, continued 
production of IFN-β, and induction of interferon stimulated genes (ISGs).   
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1.3.2 Anti-viral function of ISG15 
Support for an antiviral function for ISG15 was first reported in 2001 when it was 
found that the influenza B virus NS1 protein bound ISG15 thereby blocking the 
conjugation of ISG15 to cellular proteins (Yuan and Krug, 2001).  Since then, many 
studies have examined ISG15 and influenza virus.  In 2007, mice lacking ISG15 were 
found to be more susceptible to both influenza A and B (Lenschow et al., 2007).  Recent 
studies using Ube1L-null mice showed that the anti-viral effect of ISG15 against 
influenza B was a result of conjugated ISG15 rather than free ISG15 (Lai et al., 2009).  
Using human cell lines, Hsiang et al showed that ISG15 conjugation in human cells 
inhibited influenza A gene expression which resulted in virus replication inhibition 
(Hsiang et al., 2009).  Furthermore, inhibition of influenza A viral replication has been 
shown to be mediated by ISGylation of the viral protein, NS1 (Zhao et al., 2009).  The 
mechanism by which ISG15 conjugation inhibits influenza B replication is still unclear.  
A new study on NS1 of influenza B demonstrated that NS1B binds and sequesters human 
ISG15, but not mouse ISG15, in nuclear speckles (Sridharan et al., 2010).  This result 
may explain why mice infected with either mouse-adapted or non-mouse adapted 
versions of influenza B virus are sensitive to mouse ISG15 conjugation.     
ISG15 has also been reported to have antiviral effects against Sindbis, Vaccinia 
(VACV), Herpes Simplex I (HSV-1), murine γ-Herpesvirus 68 (γHV68), human 
immunodeficiency virus 1 (HIV-1), avian sarcoma leukosis virus (ASLV), and Ebola 
virus (Harty et al., 2009).  The first study using ISG15-null mice determined no 
difference in survival rate when infected with VSV (vesicular stomatitis virus) or LCMV 
(lymphocytic choriomeningitis virus) (Osiak et al., 2005).  A subsequent study found 
mice lacking ISG15 have increased susceptibility to influenza A and B, HSV-1, γHV68, 
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and Sindbis virus infection (Lenschow et al., 2007).  In addition, the anti-viral effect of 
ISG15 against Sindbis virus was also shown to be dependent on the conjugation of ISG15 
(Giannakopoulos et al., 2009; Lenschow et al., 2005).         
In the case of HIV-1, Ebola, and ASLV, expression of ISG15 has been shown to 
inhibit virus-like particle (VLP) release.  Two separate studies demonstrated ISG15 
inhibition of Nedd4, a Ubiquitin E3 ligase, decreased VP40 ubiquitination and Ebola 
VLP release (Malakhova and Zhang, 2008; Okumura et al., 2008).  Similarly, ISG15 was 
proposed to inhibit the release of HIV-1 VLPs by inhibiting the ubiquitination of HIV-1 
Gag and Tsg101, an ESCRT I protein required for efficient HIV-1 budding (Okumura et 
al., 2006).  A recent study on HIV-1 and ASLV VLP release suggested an additional 
mechanism exists at the last step of budding (Pincetic et al., 2010).  Pincetic et al found 
that Vps4, an ATPase which releases ESCRT complexes at the last step of budding, was 
unable to associate with HIV-1 or ASLV budding complexes in the presence of ISG15.  
ISGylation of CHMP5, an ESCRT III protein, was proposed to be ultimately responsible 
for the loss of Vps4 during the last stage of virus release.  Together these studies indicate 
possible conjugation-independent and –dependent functions for ISG15 inhibition of VLP 
budding.   
In addition to Influenza B, other viruses have also evolved mechanisms for 
interfering with ISG15 conjugation.   SARS coronavirus and human coronavirus NL63 
both encode proteases (PLpro and PLP2, respectively) that can deconjugate ISG15 from 
target proteins (Clementz et al., 2010; Lindner et al., 2007).  Vaccinia virus encodes a 
viral early protein, E3, which binds ISG15 and prevents its anti-viral activity (Guerra et 
al., 2008).  ISG15 can also be deconjugated by ovarian tumor (OTU) domain-containing 
proteases encoded by both nairoviruses and arteriviruses  (Frias-Staheli et al., 2007).   
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1.4 GOALS OF MY DOCTORAL WORK 
The goals of my doctoral work have been two-fold: 1), to understand the 
specificity of the Ube1L-UbcH8 interaction and 2), to understand the basis of substrate 
recognition by Herc5.  In 2005, Ube1L, the most closely related E1 to Uba1, and UbcH8, 
a previously reported Ub E2, had been identified as the E1 and E2 for ISG15.  Other Ubl 
pathways had dedicated E1 and E2 enzymes, so the discovery of UbcH8 represented a 
potential point of convergence between the ISG15 and Ub pathways.  In addition, it was 
unclear how Ube1L discriminated between UbcH8 and other closely related Ub E2 
enzymes.  At the same time, hundreds of cellular proteins were reported to be targets for 
ISG15 conjugation, while only one major E3 ligase, Herc5, had been identified.   
The first part of my dissertation work focused on the specific interactions between 
Ube1L and UbcH8 that allow Ube1L to discriminate between UbcH8 and closely related 
Ub E2s such as UbcH7.  Using kinetic analyses, I determined a strong preference of 
Ube1L for UbcH8 compared to UbcH7 and of Ube1 (E1Ub) for UbcH7 compared to 
UbcH8.  I then demonstrated the basis of this preference was a result of specific 
interactions between the ubiquitin-fold domain (UFD) of Ube1L and the amino-terminal 
α1-helix and β1−β2 region within UbcH8.  I also examined the interferon-induced and 
transfected expression levels of UbcH8, and combined with the kinetic constants, 
determined that UbcH8 is unlikely to function as a Ub E2 in most cell lines.  The second 
part of my dissertation work focused on the recognition of substrates by Herc5.  I 
discovered the list of target proteins that Herc5 ISGylates extends beyond the proteins 
identified by the proteomics and includes many exogenously expressed foreign proteins.  
In addition, I found that ISG15 conjugation is restricted to newly synthesized pools of 
proteins and that Herc5 is physically associated with polyribosomes.  These results led to 
35 
 
a model for ISGylation in which Herc5 broadly modifies newly synthesized proteins in a 
co-translational manner.  In a third part of my work I focused on how ISG15 modification 
of newly synthesized proteins might mediate an anti-viral effect.  In the context of a viral 
infection, newly translated viral proteins may be the targets of ISGylation.  I 
demonstrated that ISGylation of human papillomavirus (HPV) L1 capsid protein has a 
dominant-negative effect on the infectivity of HPV16 pseudoviruses.  This effect may not 
be restricted to capsid proteins; low-level ISGylation of any viral protein that 
multimerizes might have a dominant-negative effect on production of infectious virus.  
These discoveries have greatly increased our understanding of the mechanism of ISG15 
pathway and provide a framework for establishing an in vitro ISG15 conjugation system 
and further examination of the anti-viral function of ISG15. 
. 
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Chapter 2:  Methods and Materials 
2.1 MATERIALS AND METHODS FOR CHAPTER 3 
Plasmids and Mutagenesis.  Plasmids containing Ube1L, UbcH8, Herc5, and 
ISG15 were described previously.  Additional pcDNA3 (Invitrogen)-based ISG15 
plasmids were made encoding either the HA (YPYDVPDYA) epitope at the N terminus 
of ISG15 or cloning ISG15 into the pcMV10 vector, which introduces a N-terminal 3X-
FLAG epitope (Sigma).  The HA epitope was also added to the N terminus of the 
pcDNA3-Ube1L and pcDNA3-Ube1L∆UFD plasmids.  UbcH8 was introduced into the 
pcMV14 vector which contains a C-terminal 3X-FLAG epitope (Sigma).  All E2s 
(chimeric and wild type), Ube1LUFD, Ube1L∆UFD, and Ube1L-UFDUb expression 
plasmids were constructed by standard PCR ligation methods using pcDNA3 and 
pFastBac (Invitrogen) as vectors.  Sequences of all constructs were verified by DNA 
sequencing.   
Protein expression and purification.  Recombinant baculoviruses were 
generated using the Bac-to-Bac Baculovirus Expression System (Invitrogen) for the 
following: wild-type Ube1L and all Ube1L derivatives, UbcH7, UbcH8, and all chimeric 
E2 proteins.  All proteins were expressed as GST fusion proteins in High Five insect 
cells.  Insect cells were collected 48-72 hours post-infection, and lysed in buffer 
containing 1% NP-40, 100 mM Tris, pH 7.9, 100 mM NaCl, 1 mM DTT, 100 µM 
phenylmethylsulfonyl fluoride, 4 µM leupeptin, 0.3 µM aprotinin.  Proteins were affinity 
purified using GST-Bind Resin (Novagen).  Ub and ISG15 were expressed as GST fusion 
proteins using the pGEX6p-1 vector (GE Healthcare) in Escherichia coli strain BL21 
with an added cAMP-dependent kinase recognition motif (RRASV).  Cells were 
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collected and resuspended in 1X PBS containing 1% Triton and lysed by sonication.  Ub 
and ISG15 were purified on GST-Bind Resin and resuspended in 50 µl of kinase buffer 
(40 mM TRIS pH 7.5 and 20 mM MgOAc).  The proteins were labeled by adding 2 µl of 
adenosine 5’ triphosphate [γ−32P] (Perkin Elmer) and 2 µl of cAMP-dependent protein 
kinase (Promega), and the reaction mixtures were rotated at room temperature for one 
hour.  Unincorporated label was removed by washing the beads in kinase buffer.  GST 
fusion proteins on beads were subjected to site-specific cleavage with PreScission 
protease (GE Healthcare) to remove GST. All proteins, with the exception of DEAE-
purified E1Ub, were subjected to SDS-PAGE followed by staining with Coomassie blue 
G250 and quantified relative to BSA standards using a near-infrared fluorescence scanner 
(Odyssey, Li-Cor Biosciences). Ube1L and E1Ub enzymes used in Km assays were 
purchased from Boston Biochem.  E1Ub used in all other assays was expressed using a 
recombinant baculovirus in High Five insect cells (Invitrogen) and partially purified on 
DEAE-Sepharose as described previously.   
Biochemical Assays.  All thioester assays were carried out in reactions containing 
25 mM Tris (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 5 mM ATP, 0.1 mM DTT, and 2.25 
µM 32P-labeled ISG15 (~9 X 109 cpm/µmol) or 2.7 µM 32P-labeled ubiquitin (~4 X 109 
cpm/µmol).  All reactions were initiated with the addition of [32P]Ub/[32P]ISG15, 
incubated at room temperature, terminated with SDS-PAGE loading buffer lacking DTT, 
and analyzed by SDS-PAGE and autoradiography or by Bio-Rad Phosphorimager with 
Quantity One Software.  E1Ub/Ube1L activity was determined in a similar manner using 
excess E1Ub/Ube1L and minimal UbcH7/UbcH8.  All concentrations listed are of active 
enzyme.  Except where indicated, all thioester assays used 0.5 µM wild type and chimeric 
E2s.  Assays in Fig. 3.2 were incubated for 5 or 75 min and contained 0.5 µl DEAE-
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purified E1Ub/13.2 nM Ube1L.  Assays in Figure 3.4 contained 0.5 µl DEAE-purified 
E1Ub or 4.8 nM Ube1L and ISG15 samples were incubated 4 minutes, while Ub samples 
were incubated for both 1 and 10 minutes.  The reactions in Figure 3.5A contained 4.4 
nM Ube1L or Ube1L∆UFD and were incubated for 10 minutes, while the reactions in 
Figure 3.5D contained 4.4 nM Ube1L/Ube1L-UFDUb and were incubated for 5 minutes 
and 30 minutes, respectively.  For the Ube1LUFD competition assay (Figure 3.5C), 0.5 
µM UbcH8 was incubated with 0, 1, 2, or 4 µM Ube1LUFD for 3 minutes.  A reaction mix 
containing 4.4 nM Ube1L, 25 mM Tris (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 5 mM 
ATP, 0.1 mM DTT, and 2.25 µM [32P]ISG15 was added to each of the UbcH8 reactions 
for 4 minutes before the reaction was terminated.  For the Km and kcat values in Table 3.1, 
initial velocity conditions were determined for each E2 so that the E1 concentration and 
incubation time resulted in linear product formation, where less than 10% of the E2 was 
converted to E2~Ubl.  Preliminary Km assays using 0.23 nM E1Ub/3.4 nM Ube1L, and the 
proper incubation time were performed to determine the appropriate range of E2 
concentrations for each wild-type or chimeric E2 protein.  A minimum of three Km assays 
were performed and known amounts of [32P]Ub or [32P]ISG15 were included to convert 
counts to a concentration value.  After quantitation using the Bio-Rad Phosphorimager 
and Quantity One software, kinetic constants were determined using nonlinear regression 
of Michaelis-Menten plots with Graphpad Prism software.  All kinetic constants reported 
include the standard error. 
Transfection Assays.  Human HeLa and HEK293 cells were grown in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum.  
Plasmid DNA transfections were performed with cells at 80% confluence using 
Lipofectamine transfection reagent (Invitrogen).  For the experiment shown in Figure 
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3.5B, plasmids expressing Herc5 (0.5 µg), 3X-FLAG ISG15 (0.5 µg), and UbcH8 (0.25 
µg) were transfected with HA-Ube1L, HA-Ube1L∆UFD (0.25 µg), or no E1.  Cells were 
harvested and lysed 48 hours post-transfection or post-IFN-β treatment in lysis buffer 
containing 1% Nonidet P-40, 100 mM Tris, pH 7.9, 100 mM NaCl, 1 mM DTT, 100 µM 
phenylmethylsulfonyl fluoride, 4 µM leupeptin, 0.3 µM aprotinin.  30 µg of total cell 
proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane, and 
probed with anti-FLAG antibody (Sigma) to detect ISG15-conjugated proteins and anti-
HA antibody (Covance) to detect E1 expression. 
UbcH8 expression levels in HeLa cells.  For Figure 3.6, UbcH8 levels were 
determined by immuoblotting of 30 mg whole cell extracts of untreated HeLa cells (lane 
2), HeLa cells treated with 1000 units/ml of interferon-β (Berlex) for 48 hours (lane 1), or 
HeLa cells transfected with a 0.25 mg UbcH8 expression plasmid (pCMV-3X-FLAG-
UbcH8).  UbcH8 was detected with anti-UbcH8 followed by IRDye 800 goat anti-rabbit 
secondary (Licor Biosciences).  The membrane was scanned using the Odyssey system 
(Licor Biosciences) and signal intensities were quantitated with Quantity One software 
(Biorad). Transfection efficiency (33%) was determined by analysis of cells transfected 
with a GFP reporter plasmid.  
2.2 MATERIALS AND METHODS FOR CHAPTER 4 
Antibodies, Plasmids, and siRNAs.  All antibodies and target plasmids used in 
this study are listed in Tables 2.1 and 2.2, respectively.  Table 2.3 lists the ISG15 
pathway related plasmids used in this study.  The IQGAP1 SMARTpool siRNA was 
supplied by Dharmacon.  Additional siRNA sequences: p53, 5’-
GACTCCAGTGGTAATCTACTT-3’ and hTfr, 5’-AAGGTGTAGTGGAAGTATC-3’. 
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Cell Culture, IFN-β Treatment, Transfections, and Immunoblotting.  
Maintenance, transfection, harvest, and immunoblotting of HeLa and 293T cells were as 
described in section 2.1.  ISG15 conjugation was induced by treating HeLa cells with 
1000 units/mL IFN-β (Betaseron) for either 24 or 48 hours.  For the experiment shown in 
Figure 4.9, Lipofectamine 2000 (Invitrogen) was used in the initial transfection, while 
XtremeGENE siRNA Transfection Reagent (Roche) was used for the co-transfection of 
DNA and siRNA. 
35S-Labeling and Puromycin Labeling Experiments.  HEK293T cells in 35 mm 
dishes were transfected with the indicated plasmids, as described above, and labeled for 
two hours with 80µCi of 35S-cysteine (1000 Ci/mmole).  The FLAG-ISG15 construct 
used in this experiment contained the C78S mutation, eliminating the only cysteine 
residue in ISG15. The C78S mutant is fully functional for conjugation, and the use of this 
mutant ensured that the 35S-cysteine-containing proteins detected in the 
immunoprecipitation represented labeled cellular proteins that had been conjugated to 
unlabeled ISG15, as opposed to unlabeled proteins being conjugated to 35S-labeled 
ISG15.  Similarly, the ∆N-ISG15 construct lacked C78.  Cells were washed w/ PBS and 
either harvested immediately (late labeling period) or replenished with fresh media.  Cell 
lysates were collected and immunoprecipiations were performed with anti-FLAG M2 
agarose beads (Sigma). Immunoprecipitates were separated by SDS-PAGE and labeled 
proteins were detected by autoradiography. For puromycin experiments, cells were 
transfected with the indicated plasmids and treated, 24 hours post-transfection, with 
puromycin (1 mM final concentration) for 2 minutes.  Total cell extracts were prepared 
and FLAG-ISG15 conjugates were precipitated with anti-FLAG M2 agarose beads 
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(Sigma).  The immunoprecipitates were then analyzed by immunoblotting with an 
antibody recognizing puromycin.    
Sucrose Gradient Fractionation.  HEK293T or HeLa cells were harvested 24 
hours after transfection or IFN-β stimulation, as described, with the exception that 
heparin (200 µg/ml) was added to the polysome lysis buffer and RNasin was omitted.  
Lysates were centrifuged for 10 min at 16,300 x g at 4°C, and supernatants were loaded 
onto linear 7-47% (w/v) sucrose gradients containing cycloheximide (200 µg/ml). For 
EDTA treatment, cells were lysed in polysome lysis buffer containing 50 mM EDTA 
(MgCl2 and heparin omitted) before applying to a linear 10-30% (w/v) sucrose gradient 
(supplemented with 10 mM EDTA instead of MgCl2). For the RNase treatement, RNase 
(Sigma) was added to the lysate (heparin omitted) at a final concentration of 10 µg/ml 
and incubated at 30°C for 15 minutes before applying to a linear 7-47% (w/v) sucrose 
gradient. Gradients were centrifuged at 222,000 x g for 90 min (180 min for EDTA 
samples) at 4°C in a Beckmann SW41Ti rotor. Polysome profiles were monitored by 
absorbance at 254 nm and gradient fractions were collected on an ISCO density gradient 
fractionator.  Trichloroacetic acid (TCA) was added to each sucrose-gradient fraction to a 
final concentration of 10 % (v/v) for protein precipitation.  Precipitated proteins were 
then prepared for SDS-PAGE and immunoblotting analyses. 
2.3 MATERIALS AND METHODS FOR CHAPTER 5 
Transfections.  293TT cells and the plasmid p16shell expressing HPV16 L1 and 
L2 were provided by John Schiller (NCI, Bethesda, MD).  293TT cells are a 293T cell 
line stably transfected with an expression plasmid encoding a cDNA for large T antigen.  
These cells were maintained as previously described. 293TT cells were ~80% confluent 
at the time of transfection with Lipofectamine 2000 at a DNA (µg) to reagent ratio of 1:2.  
42 
 
For Figure 5.1, 293TT cells were transfected with plasmids expressing p16shell (0.5 µg) 
alone or with plasmids expressing Ube1L (0.25 µg), UbcH8 (0.25 µg), HA-Herc5 (0.5 
µg), and 3X-FLAG ISG15 (0.5 µg), or this set of plasmids without ISG15 (see also Table 
2.4).  Cells were harvested and lysed 48 hours post-transfection as previously mentioned 
in section 2.1.  Total extracts were probed with anti-HPV16 L1 antibody (Santa Cruz 
Biotechnology) followed by IRDye 800 goat anti-rabbit secondary (Licor Biosciences).  
The membrane was scanned using the Odyssey system (Licor Biosciences) to detect L1-
conjugated proteins.   
Mass Spectrometry.  293TT cells were co-transfected with p16shell and the 
ISGylation components as described above.  HPV16 L1-ISG15 conjugates were 
immunoprecipitated with anti-HPV16 L1 antibody, followed by electrophoresis on a 8% 
SDS polyacrylamide gel.  The purified protein band was analyzed by mass spectrometry 
at the Taplin Biological Mass Spectrometry Facility.   
HPV Pseudovirus Production and Infectivity Assays.  293TT cells (in 100mm 
dishes) were co-transfected with p16shell (5 µg), pcVM10-GFP (3 µg), HA-ISG15 (3 
µg), and either Ube1L (1.5 µg), UbcH8 (1.5 µg), and Herc5 (3 µg) or the inactive mutant 
enzyme forms: Ube1L-∆UFD (1.5 µg), UbcH8 F62A (1.5 µg), and Herc5 C994A (3 µg).  
After 48 hours, 293TT cells were collected and pseudovirus was purified according to the 
previously described protocols.  The lysate was applied to the Optiprep (Sigma) gradients 
and subjected to ultracentrifugation.  Fractions were collected and peak L1 content was 
determined via SDS-PAGE and immunoblotting for HPV16 L1.  Relative amounts of L1 
(ISGylated and non-ISGylated) were determined using a fluorescent secondary antibody 
and the Odyssey system (LiCor).  L1 protein concentration was determined by 
quantitation with BSA standards on colloidal Coomassie-stained SDS–PAGE gels using 
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the Odyssey system as well.  For the infection assay, 293T cells were grown in 12 well 
plates and infected with equal amounts of PsV-containing-fractions.  Sixty hours post-
infection, cells were trypsinized and subjected to FACS analysis using a FACSCalibur 
machine (Becton Dickinson).  CellQuest Pro v5.2.1 (Becton Dickinson) was used for data 
acquisition and analysis of 10,000 live cell events.  
Transmission electron microscopy (TEM).    TEM analysis of purified HPV16 
PsV was performed on carbon-coated copper grids stained with 1% uranyl acetate using a 
FEI Tecnai Transmission Electron Microscope (TEM).  Image acquired by Dwight 
Romanovicz.  
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ANTIBODIES DESCRIPTION 
Anti-Hsc70 Santa Cruz Technologies 
Anti-IQGAP1 BD Biosciences 
Anti-Ube1 Abcam 
Anti-Moesin Cell Signaling Technology 
Anti-Flag M2 Sigma Aldrich 
Anti-V5 AbD Serotec 
Anti-HA Covance 
Anti-C-Myc Covance 
Anti-TAP (Peroxidase-
anti-peroxidase) Rockland Immunochemicals for Research 
Anti-p56 Kindly provided by Ganes Sen (Cleveland Clinic, Cleveland, OH) 
Anti-Herc4 Novus Biologicals 
Anti-Herc5 Kindly provided by Enzo Life Sciences 
Anti-Puromycin Kindly provided by Peter Walter (UCSF, San Francisco, CA)  
Anti-E6AP  Prepared as described (Talis et al., 1998) 
 
Table 2.1: Antibodies used in Chapters 4 and 5. 
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PLASMID  DESCRIPTION 
pc3XFLAG-ISG15 & 
pcHA-ISG15 Previously described (Zhao et al., 2005) 
pcFLAG-ISG15 & 
pcFLAG-∆N-ISG15 
Plasmids were made by introducing a sequence encoding an 
N-terminal FLAG epitope (DYKDDDDK) into a pcDNA3.1 
plasmid containing either full length human ISG15 or residues 
80-158 of ISG15 (∆N) 
pcDNA Ube1L Previously described (Zhao et al., 2005) 
pcDNA Ube1L∆UFD Previously described (Durfee et al., 2008) 
pcDNA UbcH8 Previously described (Zhao et al., 2005) 
pcDNA UbcH8 F62A Previously described (Dastur et al., 2006) 
pCS2+MT (Myc)-Herc5 M. Ohtsubo of Hiroshima University 
pcTAP Herc5 pcTAP 
Herc5 C994A Previously described (Dastur et al., 2006) 
pcHA-Herc5, pcHA-
Herc5∆RCC, and pcHA-
∆100 
Herc5, Herc5∆RCC, and Herc5∆100 were subcloned from the 
pcTAP vector into the pcHA vector (Dastur et al., 2006) 
pcTAP IQGAP1, A, B, 
C 
The cDNA of IQGAP1 was previously described (Ho et al., 
1999). 
pcMV10 IQGAP1 Same as above, but IQGAP1 was cloned into the pcMV10 vector.   
pcTAP Ube1 
Ube1 was previously described (Beaudenon and Huibregtse, 
2005; Huibregtse et al., 1995), and was subcloned into the 
pcTAP vector. 
pcV5 Ube1 Same as above, but Ube1 was cloned into the pcV5 vector. 
pcHA Ube1 Same as above, but Ube1 was cloned into the pcHA vector. 
pcV5 Moesin Previously described (Zhao et al., 2005) 
pcV5 TrxR1 Previously described (Zhao et al., 2005) 
pcV5 Ran Previously described (Zhao et al., 2005) 
pcFLAG Cofilin Cofilin cDNA was cloned into the pcFLAG vector. 
pcTAP Hsc70 pcTAP Hsc70 was provided by R. Krug. 
pcMyc Hsc70 pcMyc Hsc70 was provided by Dr. D. Manor. 
pcTAP p56 
His-3X FLAG-p56 was provided by Dr. Robert Krug (UT 
Austin, Austin, TX), and was subcloned into the pcTAP 
vector. 
pcTAP MxA, A, B pcTAP MxA was provided by Dr. Robert Krug (UT Austin, 
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Austin, TX), and was used to generate the TAP fusion 
proteins A and B.   
pcMV10 MxA Same as above, but MxA was cloned into the pcMV10 vector.   
pcTAP Previously described (Dastur et al., 2006) 
pcTAP E6AP (C-A 
mutant) 
The cDNA of E6AP C-A mutant was previously described 
(Huibregtse et al., 1995), and was subcloned into the pcTAP 
vector. 
pcHA p53 The cDNA of p53 was previously described (Huibregtse et al., 1991), and was subcloned into the pcHA vector. 
pcTAP p53 Same as above, but p53 was subcloned into the pcTAP vector.   
pcHA β-Gal β-Gal was amplified from pSVβgal (Promega) and cloned into the pcHA vector. 
pcTAP Herc6 (C-A 
mutant) 
Herc6 was amplified from cDNA, cloned into the pcTAP 
vector, and the active site cysteine mutated (C985A). 
pcTAP p56 
His-3X FLAG-p56 was provided by Dr. Robert Krug (UT 
Austin, Austin, TX), and was subcloned into the pcTAP 
vector. 
pcTAP HIV Integrase HIV-1 Integrase cDNA was subcloned into the pcTAP vector.   
pcTAP SopA The cDNA of SopA was subcloned from a plasmid provided by J. Chen (Purdue University) into the pcTAP vector. 
p16shell, p18shell Provided by John Schiller (NCI, Bethesda, MD) 
pcV5-HPV18L1 HPV18 L1 ORF was cloned into the pcV5 vector 
pcTAP OSPG OSPG was amplified from Shigella genomic DNA provided by S. Payne, and cloned into the pcTAP vector. 
pcFLAG Dlg Dlg cDNA (Lee et al., 1997), and was cloned into pcFLAG vector. 
pcMV10 GFP GFP was amplified from pEGFP-C1 (Clontech) and cloned into the pcMV10 vector (Sigma) 
Table 2.2: Plasmids used in Chapters 4 and 5 
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Chapter 3: The basis for selective E1-E2 interactions in the ISG15 
conjugation system 
3.1 INTRODUCTION 
Ub and Ubls are covalently conjugated to proteins through amide bonds formed 
between their terminal carboxyl groups and, in most cases, ε-amino groups of lysine 
residues of target proteins. Two groups of enzymes, the E1 and E2 enzymes, are essential 
for all known Ub/Ubl conjugation pathways. These enzymes function cooperatively in 
reactions that involve enzyme-bound thioester intermediates (Pickart, 2001).  E1 enzymes 
catalyze Ub/Ubl activation by first forming an ATP-dependent Ub/Ubl-adenylate, 
followed by an enzyme-bound Ub/Ubl-thioester at the active-site cysteine of the E1.  The 
activated E1 then transfers the Ub/Ubl to the active-site cysteine of specific E2 enzymes 
in a transthiolation reaction, preserving the Ub-thioester linkage.  In some cases, the E2 
may directly interact with target proteins (e.g., Ubc9 in Sumo conjugation (Melchior, 
2000)), however conjugation of Ub and most Ubls requires E3 activities. E3s function 
minimally as docking or scaffolding proteins, binding both the activated E2 and a 
substrate protein, orienting them for reaction of the ε-amino group of a lysine side chain 
of the target protein with the activated carboxyl group of the Ub/Ubl.  In the case of the 
HECT domain E3s, the E2 transfers Ub to the active-site cysteine of the E3, with the E3 
directly catalyzing the final transfer to the target protein (Scheffner et al., 1995).   
The E1, E2, and E3 enzymes for conjugation of Ub and Ubls are generally highly 
specific for function with either Ub or a single Ubl (Kerscher et al., 2006), however 
potential overlap of the conjugation pathways for Ub and ISG15 was suggested based on 
identification of the ISG15 E2 enzyme (Kim et al., 2004; Zhao et al., 2004).  ISG15 is a 
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17 kDa Ubl that is rapidly and strongly induced by type-1 interferons (IFN-α/β). Over 
300 cellular proteins are modified by ISG15 in IFN-β-treated cells (Giannakopoulos et 
al., 2005; Wong et al., 2006; Zhao et al., 2005).  The E1 and E2 enzymes for ISG15 are 
Ube1L and UbcH8, respectively, and like ISG15, expression of both proteins is induced 
at the transcriptional level by IFN-α/β  (Kim et al., 2004; Nyman et al., 2000; Yuan and 
Krug, 2001; Zhao et al., 2004).  Depletion of UbcH8 by siRNAs eliminates virtually all 
ISG15 conjugation in IFN-β-treated cells, while depletion of the most closely related E2, 
UbcH7 (55% identity, 72% similarity to UbcH8), had no effect on ISG15 conjugation 
(Zhao et al., 2004).  These results strongly suggest that UbcH8 is the only E2 enzyme for 
the ISG15 pathway. UbcH8 has been reported in several cases to function in Ub 
conjugation pathways (Chin et al., 2002; Urano et al., 2002; Wheeler et al., 2002; Zhang 
et al., 2000), often in a manner that is redundant with UbcH7 (Fortier and Kornbluth, 
2006; Imai et al., 2000; Moynihan et al., 1999; Shimura et al., 2000), suggesting that 
UbcH8 might function in both the Ub and ISG15 conjugation systems.  Importantly, 
given the functional redundancy of E2s in the Ub system, it is difficult to unambiguously 
demonstrate that UbcH8 functions in conjugation in vivo. The fact that UbcH8 expression 
is transcriptionally regulated by IFN-α/β signaling suggests that there may be insufficient 
amounts of UbcH8 protein present in most cell types in the absence of interferon to 
significantly influence Ub conjugation.   
Structural and biochemical studies on Sumo and Nedd8 E1s have revealed the 
basis for interaction of these enzymes with their cognate E2 enzymes (Huang et al., 2005; 
Lois and Lima, 2005).  Both of these E1s are heterodimeric enzymes (Sae1/Sae2 for 
Sumo, AppBp1/Uba3 for Nedd8), with the Sae1 and AppBp1 proteins corresponding to 
the N-terminal domain of monomeric E1s, and the Sae2 and Uba3 proteins corresponding 
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to the C-terminal domain of monomeric E1s.  Interestingly, a domain at the C-terminus of 
the Sae2 and Uba3 proteins adopts a structure that resembles ubiquitin (the Ub-fold 
domain; UFD).  The UFD is the primary site for interaction of Sae2 and Uba3 with their 
cognate E2 enzymes (Ubc9 and Ubc12, respectively). Ube1L is also predicted to contain 
a C-terminal UFD (Huang et al., 2005).  The core region of Ubc12 that interacts with the 
UFD is primarily the first alpha helix and the β1- β2 loop (Huang et al., 2005), and the 
analogous regions of Ubc9 were identified by mutagenesis as the E1Sumo interacting 
domain (Bencsath et al., 2002).  These results were consistent with earlier work that 
suggested that the N-terminal regions of Ub E2s were critical for interacting with E1Ub 
(Pitluk et al., 1995; Sullivan and Vierstra, 1991). 
We initiated the current study study to determine the basis for specific Ube1L-
UbcH8 interactions in the ISG15 system, and in particular, to identify the features that 
distinguish UbcH8 from UbcH7 in its ability to be activated by Ube1L.  Consistent with 
the studies described above, two primary determinants within the E2 N-terminal region 
(the α1 helix and β1−β2 region) were responsible for the differential interaction of 
UbcH8 and UbcH7 with Ube1L.  The UFD of Ube1L bound specifically to UbcH8 and 
was essential for transfer of ISG15 to UbcH8.  In addition, E1Ub was found to 
discriminate against activation of UbcH8 to a similar degree as Ube1L discriminated 
against UbcH7, suggesting that UbcH8 may be limited in its capacity to function in Ub 
conjugation in vivo.    
3.2 RESULTS 
3.2.1 E2~ISG15 thioester formation in vitro. 
UbcH7 is 55% identical and 72% similar to UbcH8 and is the most closely related 
E2 to UbcH8 among all human E2 enzymes.  Figure 3.1A shows an alignment of the 
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UbcH8 and UbcH7 protein sequences, along with their common secondary structure 
elements as determined from X-ray crystal structures (UbcH8: PDB 1WZW, K. Tanaka 
and colleagues, unpublished; UbcH7: PDB 1D5F (Huang et al., 1999)). Both proteins 
belong to the subgroup of E2s defined, in part, by a conserved sequence motif within the 
amino-terminal α-helix (α1): xRφxx[D/E]x (where x is any residue and φ is a 
hydrophobic residue) (Winn et al., 2004).  This motif constitutes residues 4-10 of UbcH8 
and represents the most common motif found in the α1 helix among all ubiquitin E2s 
(Winn et al., 2004).  With the exception of UbcH8, none of the E2s in this subgroup have 
been reported to function with Ubls other than Ub. UbcH7 and UbcH8 both contain a 
conserved phenylalanine residue (F63 in UbcH7, F62 in UbcH8) that is a key contact for 
interaction of these proteins with HECT and RING E3s (Huang et al., 1999; Zheng et al., 
2000), and both proteins consist solely of the approximately 150 amino acid common 
core E2 structure with no amino- or carboxyl-terminal extensions.  Comparing the 
sequences of the two proteins, the longest contiguous stretch of non-conserved residues is 
the six-residue random coil linker between the first alpha helix and the first beta strand 
(α1-β1 linker; residues 16 to 21 of UbcH8), where the UbcH8 sequence is KPPPYL and 
UbcH7 is CGMKNF.  The α1 helix, the linker, and the β1-β2 region are highlighted in 
the UbcH8 ribbon structure shown in Figure 3.1B.   
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Figure 3.1: Sequence and structure of UbcH8. 
A) Alignment of the UbcH8 and UbcH7 sequences, with secondary structure elements of 
UbcH8 indicated.  Numbering is according to UbcH8 residues.  Residues in red represent 
identical residues, green represent similar residues.  
B) Structure of UbcH8 (PDB 1WZW, K. Tanaka and colleagues, unpublished).  The α1 
helix (red) and β1-β2 region (green) are indicated, along with the linker connecting these 
elements and the active site cysteine (C85, pink). 
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Both UbcH7 and UbcH8 have been reported previously to cooperate with E1Ub in 
catalyzing protein ubiquitination in vitro and in vivo (Kumar et al., 1997; Moynihan et al., 
1999), while only UbcH8 functions in ISG15 conjugation in vivo (Zhao et al., 2004).  To 
determine if these results are consistent with biochemical characteristics of E1Ub and 
Ube1L, we performed a preliminary examination of E1-E2 interactions using in vitro 
thioester assays and incubation times of either 5 or 75 minutes.  As shown in Figure 3.2, 
at the 5 minute time point, E1Ub preferentially transferred Ub to UbcH7 compared to 
UbcH8.  At the 75 minute time point the differences in UbcH7 and UbcH8 Ub thioester 
formation were minimized.  Similar results were seen with ISG15 thioester assays, where 
UbcH8 activation was detected at the 5 minute time point, while UbcH7 activation was 
almost undetectable, but at the 75 minute time point the differences between UbcH8 and 
UbcH7 activation were minimized.  These results indicate that both UbcH7 and UbcH8 
can be charged with both Ub and ISG15 to varying degrees.  They also demonstrate that 
in vitro experimental conditions may lead to inaccurate conclusions regarding E1 and E2 
cooperativity, and suggested the need for more quantitative kinetic analyses. 
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Figure 3.2: E1-E2 thioester assays with wild-type UbcH7 and UbcH8. 
Thioester complex formation was analyzed after incubation with E1Ub or Ube1L for 
either 5 minutes (top panel) or 75 minutes (bottom panel) with wild-type UbcH7 or 
UbcH8.  The Ub and ISG15 were labeled with 32P and thioester adducts were detected by 
autoradiography.  
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The Km values of E1Ub and Ube1L for both UbcH7 and UbcH8 (Table 3.1) were 
determined by quantifying E2~Ub/ISG15 thioester formation under initial rate 
conditions, using 32P-labeled Ub and ISG15 (Table 3.1).  The Km of Ube1L for UbcH8 
was determined to be 66 +/-8 nM and for UbcH7 it was approximately 29-fold higher 
(1891 +/- 368 nM).  This difference was consistent with the fact that neither endogenous 
UbcH7 nor any other Ub E2 can substitute for UbcH8 in ISG15 conjugation in interferon-
treated cells (Zhao et al., 2004).  Similarly, the Km of E1Ub for UbcH7 was determined to 
be 185 +/- 26 nM and for UbcH8 it was approximately 36-fold higher (6645 +/- 136 nM).  
The ratio of Kcat/Km is an indicator of the specificity of an enzyme for a substrate, and 
this value for E1Ub was approximately 1,300-fold greater with UbcH7 than with UbcH8 
(65,450 versus 51 s-1M-1; Table 1).  For Ube1L, Kcat/Km was approximately 114-fold 
greater with UbcH8 than with UbcH7 (42,580 versus 372 s-1M-1).  Together, these kinetic 
parameters are consistent with previous demonstrations (Zhao et al., 2004) that no other 
endogenous E2 proteins can substitute for UbcH8 in the ISG15 system in vivo.  
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Table 3.1: Kinetic constants of E1Ub and Ube1L for formation of E2~ubiquitin and 
E2~ISG15 thioesters. 
 
3.2.2 Residues 1-39 are critical for UbcH8 interaction with Ube1L in vitro. 
To identify the determinants of UbcH8 that confer specificity for Ube1L, we 
expressed and purified a set of chimeric UbcH8-UbcH7 proteins (Figure 3.3).  These 
proteins were assayed for ISG15 thioester formation with purified Ube1L and 32P-labeled 
ISG15, as well as for Ub thioester formation with E1Ub and 32P-labeled Ub (Figure 3.4).  
To ensure incubation times were within the initial velocity period, reaction progress 
curves were examined for UbcH8 with Ube1L and UbcH7 with E1Ub.  Two time points 
were used for Ub thioester assays, as UbcH8~Ub thioester formation was nearly 
undetectable after one minute.  Chimeras A and B, containing either the N-terminal 39 or 
70 residues of UbcH8, functioned similar to UbcH8 in ISG15 thioester formation (87% 
E1   E2 kcat (s-1) Km (nM) kcat/Km (s-1M-1) 
E1Ub (Ub) UbcH7 0.0115 +/- 0.001 185 +/- 26 65500 +/- 13000 
E1Ub UbcH8 0.000340 +/- 0.0001 6650 +/- 140 50.7 +/- 19 
Ube1L (ISG15) UbcH7 0.000620 +/- 0.00001 1890 +/- 370 372 +/- 180 
Ube1L UbcH8 0.00265 +/- 0.0003 66.4 +/- 8.3 42600 +/- 790 
Ube1L A 0.000778 +/- 0.0004 86.1 +/- 33 8560 +/- 670 
Ube1L D 0.00218 +/- 0.0001 1770 +/- 150 1240 +/- 53 
Ube1L H 0.00282 +/- 0.0009 86.9 +/- 19 33900 +/- 10000 
Ube1L J 0.00106 +/- 0.0001 1940 +/- 220 573 +/- 130 
Ube1L K 0.00181 +/- 0.0002 1750 +/- 290 1210 +/- 370 
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and 89%, respectively, relative to UbcH8), while thioester formation with chimera C 
(containing residues 1-122 of UbcH7) was undetectable.  These results suggested that the 
N-terminal 39 residues of UbcH8 contain the major determinants for productive 
interaction with Ube1L.  Interestingly, chimera C formed a Ub thioester with similar 
efficiency as wild-type UbcH7 in reactions programmed with E1Ub, suggesting that the 
determinants of E1Ub-UbcH7 specificity correspond, at least broadly, to the determinants 
of Ube1L-UbcH8 interaction.  Chimeras A and B also formed Ub thioesters at a 
relatively low efficiency, similar to wild-type UbcH8, further suggesting that the N-
terminal regions of UbcH8 and UbcH7 direct specificity for Ube1L and E1Ub, 
respectively.  
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Figure 3.3: Schematic of chimeric and mutant E2 proteins. 
UbcH8 sequences are shown in black and UbcH7 sequences are shown in gray.  
Numbering at chimera junctions represents the first residue (if the chimera contains 
UbcH8 in its C-terminus) of the last residue (if the chimera contains UbcH8 in its N-
terminus) of the UbcH8 sequence present in the chimera.  Specific amino acid changes 
are shown for some chimeras and mutants.  
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Additional chimeras (Figure 3.3) were made to further localize the determinants 
of UbcH8 required for functional interaction with Ube1L.  Surprisingly, chimeras D and 
E, containing only the first 14 or first 7 residues of UbcH8, were positive for ISG15 
thioester formation (at 23% and 24%, respectively, of level of UbcH8; Figure 3.4A, B).  
Chimera D contains the complete α1 helix, while E contains the amino terminal half of 
the α1 helix, which includes the conserved E2 sequence motif described above 
(xRφxx[D/E]x, where φ is a hydrophobic residue and R is residue 5 of UbcH8).   One 
significant difference between UbcH8 and UbcH7 within this region is that UbcH8 
contains a methionine at residue 4, while UbcH7 contains an arginine at the analogous 
position.  The M4R mutant of UbcH8 (chimera F) was diminished in thioester formation 
by 31% relative to UbcH8.  In addition to residue 4, UbcH8 contains VV at residues 6-7, 
whereas UbcH7 contains LM at the analogous positions.  ISG15 thioester formation was 
decreased by 69% when the LM sequence replaced the VV sequence of UbcH8 (chimera 
G).  Furthermore, chimeras F and G functioned much better with Ub than wild-type 
UbcH8 when incubated for 10 minutes.  These results indicate that the α1 helix of 
UbcH8 is an important determinant, but not the sole determinant, of specificity for 
Ube1L. 
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Figure 3.4: In vitro Ub and ISG15 thioester assays with chimeric E2s. 
A) Equivalent amounts of the indicated E2 proteins were incubated with 32P-ISG15 and 
Ube1L for four minutes (top panel), 32P-Ub and E1Ub (DEAE purified) for one minute 
(middle panel), or 32P-Ub and E1Ub (DEAE purified) for ten minutes (bottom panel).  
Reaction products were analyzed by SDS-PAGE without reducing agent. 
B) E2 thioester adducts were quantitated and are represented as a percentage relative to 
UbcH8 (for ISG15 thioesters; upper panel); or relative to UbcH7 (for Ub thioesters; 
lower panel). 
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As noted above, linker residues between the α1 helix and the β1 sheet (UbcH8 
resides 16-21) are very divergent between UbcH8 and UbcH7, and we therefore 
addressed whether these residues contributed to the specificity of UbcH8 for Ube1L in 
vitro.  A chimera was constructed with the linker residues from UbcH7 replacing those of 
UbcH8 (chimera H).  This resulted in a 19% decrease in thioester formation relative to 
UbcH8.  A more dramatic decrease of 62% was observed when UbcH8 residues 17-19 
(PPP) were mutated to AAA (chimera I).  Ub thioester formation with chimera H was 
comparable to UbcH8 while no Ub thioester formation was observed with chimera I. This 
suggests that the linker sequence might not be a direct determinant of specificity for 
Ube1L, but rather that alterations of this sequence might have deleterious structural 
effects on the orientation of the α1 helix or the β1−β2 region (discussed further below).  
Consistent with this possibility, the crystal structure of Ubc12core with a fragment of Uba3 
revealed no interaction of the UFD with the corresponding Ubc12core α1-β1 linker.   
The third region the N-terminal 39 residues with the potential to influence Ube1L 
interactions was the β1-β2 region (residues 21-39). ISG15 thioester formation of Chimera 
K (containing residues 22-152 of UbcH8) was 22% of that of UbcH8, while thioester 
formation of chimera J (containing residues 21-154 of UbcH7) was 27% of UbcH8.  This 
indicates that the UbcH8 β1-β2 region contributes to ISG15 thioester formation, but that 
it is not sufficient for full activation. There are few amino acid differences between 
UbcH7 and UbcH8 within the β1-β2 region, however UbcH8 contains SS at resides 25-
26 while UbcH7 contains QV at the analogous positions.  When these residues were 
exchanged in UbcH8 (chimera L), ISG15 thioester formation was reduced by 13%, and 
this chimera functioned four-fold better than UbcH8 with E1Ub.  These results are 
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consistent with the β1-β2 region of UbcH7 and UbcH8 being an additional determinant 
of E1 recognition. 
Kinetic analyses of select chimeras were used to further analyze the role of 
structural elements within the first 39 residues of UbcH8.  Replacement of the α1-helix 
or β1-β2 region of UbcH8 with UbcH7 residues (chimeras D, K, or J) resulted in a 27-29-
fold increase in the Km of Ube1L compared to wild-type UbcH8 (Table 3.1).  These 
chimeras also showed a large decrease in kcat/Km compared to UbcH8. In contrast, 
residues in the linker region (chimera H) had a Km and kcat similar to that of wild-type 
UbcH8.  This was reflected in a kcat/Km ratio that was 80% that of UbcH8 compared to 
ratios approximately 1-3% of UbcH8 for chimeras D, K, and J.  Finally, the Km of Ube1L 
for chimera A, containing the first 39 residues of UbcH8, was very similar to that of wild-
type UbcH8, although kcat/Km for chimera A was approximately 5-fold lower than 
UbcH8.  This suggests that chimera A contains the determinants necessary for efficient 
Ube1L interaction, but that it may be partially defective for accepting ISG15 from 
Ube1L.  Overall, these results are consistent with the UbcH8 α1-helix and β1-β2 regions 
being the primary elements recognized by Ube1L.   
2.2.3 Interaction of UbcH8 with the UFD of Ube1L. 
The Sae2 and Uba3 proteins, components of the Sumo and Nedd8 E1 enzymes, 
respectively, contain a C-terminal Ub fold domain (UFD).  This is the primary site for 
interaction with the core domains of their appropriate E2 enzymes (Huang et al., 2005; 
Lois and Lima, 2005).  It was proposed that the C-terminus of Ube1L is also likely to 
contain a UFD based on structural propensities of residues conserved with Uba3.  To 
determine whether the UFD of Ube1L has a similar role as in Sae2 and Uba3, a C-
terminal deletion mutant of Ube1L (Ube1L∆UFD) was constructed, lacking the last 102 
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amino acids of the protein (residues 911-1012).  If the UFD is the site of interaction with 
UbcH8 then the Ube1L∆UFD would be predicted to be able to form an ISG15 thioester, 
but be unable to transfer ISG15 to UbcH8.  As shown in Figure 3.5A, this was the case. 
In addition, the Ube1L∆UFD mutant did not support ISG15 conjugation when co-
transfected with ISG15, UbcH8, and Herc5 into non-interferon-treated HEK293 cells 
(Figure 3.5B).   
The purified UFD fragment of Ube1L (consisting of residues 902-1013) was 
predicted to compete with full-length Ube1L for binding to UbcH8, and as shown in 
Figure 3.5C, the UFD inhibited UbcH8~ISG15 thioester formation in a concentration-
dependent manner.  Finally, a chimeric Ube1L protein was created in which the UFD of 
Ube1L was replaced with the UFD from E1Ub (Ube1L-UFDUb; replaces residues 910-
1013 of Ube1L with residues 951-1059 of E1Ub). In vitro, Ube1L-UFDUb would be 
expected to transfer ISG15 preferentially to UbcH7, rather than UbcH8, and this was 
indeed the case (Figure 3.5D).  The chimeric Ube1L-UFDUb protein was much less stable 
and less active than wild-type Ube1L, and therefore the absolute efficiencies of 
UbcH7~ISG15 thioester formation in the presence of the chimeric and wild-type Ube1L 
enzymes were not directly comparable.  Nevertheless, the fact that the chimeric Ube1L 
preferentially transferred ISG15 to UbcH7 over UbcH8 is consistent with a model where 
the primary determinants of E1-E2 interactions in the ISG15 system are specified by the 
UFD of Ube1L with the α1 helix and β1-β2 region of UbcH8. 
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Figure 3.5: The UFD of Ube1L is required for the interaction with UbcH8. 
A) 32P-ISG15 was incubated for 10 minutes with Ube1L or Ube1L∆UFD, with the 
indicated E2 proteins, and reactions were analyzed by SDS-PAGE without reducing 
agent.  An E2-independent background band is indicated (*). 
B) HEK293 cells were transfected with plasmids expressing 3X FLAG-ISG15, UbcH8, 
Herc5, and either HA-Ube1L, no Ube1L, or HA-Ube1L∆UFD.  Cell extracts were 
prepared and analyzed by immunoblotting with anti-FLAG antibody to detect ISG15 
conjugates (left panel).  Expression of HA-Ube1L and HA-Ube1L∆UFD was confirmed 
using anti-HA antibody (right panel). 
C) The purified UFD of Ube1L is a competitive inhibitor of UbcH8~ISG15 thioester 
formation.  UbcH8 thioester formation was analyzed as in (A), with increasing amounts 
of purified UFD protein present in the reaction (expressed as the molar ratio of UFD to 
UbcH8 protein). 
D) A chimeric Ube1L protein containing the UFD of E1Ub (Ube1L-UFDUb) preferentially 
transfers ISG15 to UbcH7.  32P-ISG15 was incubated with Ube1L or Ube1L-UFDUb and 
either no E2, UbcH7, or UbcH8.  Reaction products were analyzed by SDS-PAGE 
without reducing agent.  An E2-independent background band is indicated (*).   
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3.2.4 Endogenous versus exogenous UbcH8 expression levels. 
UbcH8 was initially reported to function in the conjugation of ubiquitin both in 
vitro and in vivo.  As reported above, long incubation times and/or high enzyme 
concentrations in vitro can lead to inaccurate results regarding pathway specificity for 
UbcH8.  A large number of studies suggesting UbcH8 functions as a ubiquitin E2 draw 
conclusions based on experiments where UbcH8 was expressed by transfection (Chin et 
al., 2002; Niwa et al., 2001; Wheeler et al., 2002; Zhang et al., 2000).  We compared the 
expression levels of UbcH8 in HeLa cells after induction with interferon versus 
transfection of a CMV promoter-based UbcH8 expression vector (Figure 3.6). On a per 
cell basis, the level of UbcH8 in the transfected cells was approximately 60-fold higher 
than the level of UbcH8 in the interferon-treated cells.  These results, in addition to the 
kinetic constants determined above, strongly suggest that overexpression of UbcH8 by 
transfection in vivo can potentially lead to the inaccurate designation of UbcH8 as a 
ubiquitin E2.   
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Figure 3.6: Protein expression levels of UbcH8 in HeLa cells. 
UbcH8 levels were determined by immuoblotting of 30 mg whole cell extracts of 
untreated HeLa cells (lane 2), HeLa cells treated with 1000 units/ml of interferon-β for 
48 hours (lane 1), or HeLa cells transfected with a 0.25 µg UbcH8 expression plasmid 
(pCMV-3X-FLAG-UbcH8).   
 
 
3.3 DISCUSSION 
The inherent similarities between Ub and Ubls and the enzymes of their 
conjugation systems leads to important questions about whether all Ub/Ubl pathways are 
separate and distinct, and if so, how specificity is determined.  We have shown here that 
the basis for Ube1L-UbcH8 specificity is similar to that described previously in the Sumo 
and Nedd8 systems: interactions between the UFD of the Ube1L and the α1 helix and β1-
β2 regions of UbcH8 are the major specificity determinants.  Subtle differences in these 
regions between UbcH8 and UbcH7 are sufficient to allow effective discrimination 
against this very closely related Ub E2.  Furthermore, the degree to which Ube1L 
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discriminates against UbcH7 (based on Kms) is similar to the degree to which E1Ub 
discriminates against UbcH8, raising the question of whether UbcH8 functions in the Ub 
system.  Similar results and conclusions concerning the role of UbcH8 in Ub conjugation 
have been discussed previously (Haas, 2006).  
A UbcH8-UbcH7 chimeric E2 containing residues 1-39 of UbcH8 (chimera A) 
could interact efficiently with Ube1L. Within this N-terminal region, both the α1 helix 
and the β1-β2 region contributed to Ube1L specificity.  Kinetic assays with chimeras 
containing either the α1 helix or the β1-β2 region of UbcH7 resulted in Km and kcat/Km 
values similar to those of UbcH7.  Within the α1 helix, there are only three non-
conserved residues and alteration of these residues in UbcH8 to those found in UbcH7 
decreased in vitro E2~ISG15 thioester formation significantly, while E2~Ub thioester 
formation was correspondingly increased.  Two of the three residues, M4 and V7, 
correspond in position to residues of Ubc12 that make key interactions with the Uba3 
component of the Nedd8 E1 (Huang et al., 2007; Huang et al., 2005).   
The β1-β2 region also contributed to Ube1L-UbcH8 specificity (comparing, for 
example, chimeras A and J in ISG15 thioester formation), however it is likely that 
multiple subtle differences between UbcH8 and UbcH7 within this region contribute to 
this specificity.  SS25-26 is the most divergent dipeptide in this region of UbcH8 (QV26-27 
in UbcH7), and the residue corresponding to UbcH8 S26 in the Ubc9p and Ubc12 
structures was previously shown to be important for SUMO and Nedd8 thioester 
formation, respectively.  Exchange of SS25-26 in UbcH8 for QV26-27 led to a small but 
significant decrease in ISG15 thioester formation. Interestingly, this mutant formed a Ub 
thioester with an approximately 4-fold increased efficiency relative to wild-type UbcH8. 
It is therefore possible that SS25-26 may serve less as a specificity determinant for Ube1L-
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UbcH8 interaction than as a barrier to E1Ub-UbcH8 interaction.  A role for such barriers 
in establishing E1-E2 specificities has recently been proposed in an analysis of the Nedd8 
E2, Ubc12, where it was shown that certain surface residues of Ubc12 appear to function 
more in preventing mischarging by E1Ub than in specifying charging by the Nedd8 E1 
(Huang et al., 2008).   
The third structural element within residues 1-39 of UbcH8 is the linker between 
α1 and β1, and it is the most divergent region of sequence over the entire length of 
UbcH7 and UbcH8.  A direct swap of UbcH7 linker into UbcH8 however, had little 
effect on the Km of chimera H compared to wild type UbcH8.  Furthermore, comparison 
of chimeras J (UbcH8 α1-helix and linker) and D (UbcH8 α1-helix only) revealed only a 
minor difference in thioester formation, suggesting that the linker sequence per se is not a 
determinant of Ube1L-UbcH8 specificity.  This is consistent with the fact that the 
corresponding element in Ubc12 does not make contact with the Uba3 UFD in the co-
crystal structure (Huang et al., 2005). 
As in the Sumo and Nedd8 E1s, the C-terminal UFD of Ube1L is essential for 
transfer of ISG15 to UbcH8 and a chimeric Ube1L containing the UFD from E1Ub 
preferentially transferred ISG15 to UbcH7 over UbcH8.  The fact that the chimeric 
Ube1L-UFDUb protein had very low activity compared to wild-type Ube1L precluded 
analyses to determine whether the UFD was the sole determinant of E2 specificity, and 
based on detailed structural studies of Ubc12 with the Nedd8 E1 complex it is likely that 
there is an additional surface(s) involved in the Ube1L-UbcH8 interaction (Huang et al., 
2008).  Nevertheless, the results presented here strongly support a model in which the 
primary basis for preferential transfer of ISG15 to UbcH8 is the ability to recruit the E2 
via the UFD. 
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Interestingly, before UbcH8 was shown to be E2 for the ISG15 system (Kim et 
al., 2004; Zhao et al., 2004), it was reported to be an E2 for the Ub system (Chin et al., 
2002; Fortier and Kornbluth, 2006; Shimura et al., 2000; Urano et al., 2002; Wheeler et 
al., 2002; Zhang et al., 2000).  However, endogenous UbcH8 expression levels are very 
low in most non-interferon human cell lines, including HeLa, A549, and HEK293 cells, 
where it is virtually undetectable by immunoblotting (see Figure 3.6).  While interferon-β 
treatment of HeLa cells leads to the induction of UbcH8, transient transfection of a CMV 
promoter-based UbcH8 expression vector led to an approximately 60-fold higher level of 
UbcH8 over the interferon-induced level of endogenous UbcH8.  Combined with the 
relatively high Km of E1Ub for UbcH8, these observations suggest that 1) UbcH8 is 
unlikely to function in Ub conjugation in many commonly utilized cell lines (at least in 
the absence of interferon stimulation), and 2) that experimental overexpression may lead 
to such high levels of UbcH8 that the relatively high Km of E1Ub for UbcH8 might be 
overcome, allowing it to function in Ub conjugation and leading to potentially erroneous 
conclusions regarding the participation of UbcH8 in Ub-dependent processes.  
Alternatively, there may be cell or tissues types where UbcH8 expression is sufficient to 
allow its utilization in the Ub system.   For example, global microarray gene expression 
profiling suggests that UbcH8 may be preferentially expressed in certain cells of the 
immune system (Su et al., 2002).  Finally, a second E1 enzyme for Ub has been recently 
described, Uba6/E1-L2, raising the possibility that UbcH8 might normally be activated 
with Ub through Uba6 rather than E1Ub (Ube1) (Chiu et al., 2007; Jin et al., 2007).   
However, in end-point thioester assays, UbcH8 was not activated with Ub any more 
efficiently by Uba6 than E1Ub (Ube1) (Jin et al., 2007). 
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If UbcH8 does not function in Ub-dependent processes, why has the ISG15 
system evolved to utilize an E2 that is so similar to UbcH7 (as well as other related E2s, 
such as the UbcH5 family of E2s)?  Why has UbcH8 not diverged more extensively from 
E2s of the Ub system?  One possibility may be related to the fact that the major E3 for 
the ISG15 system is a HECT E3, Herc5 (Dastur et al., 2006).  Herc5 is the only HECT E3 
known to function with a modifier other than Ub, and because of inherent HECT E3 
structure and/or the unique mechanism of HECT E3s, Herc5 might place considerable 
constraints on the how far the primary sequence of UbcH8 can diverge from other human 
E2s that function with HECT E3s (e g., UbcH5a, b, c, UbcH6, UbcH7).   
Interestingly, there are other features of the ISG15 system that more closely 
resemble features of the Ub system than other Ubl systems.  For example, human Ube1L 
is the most closely related E1 enzyme to human Ube1/E1Ub, and ISG15 is the only Ubl 
where the last six residues of the protein (LRLRGG) are identical to that of Ub.  Are 
these similarities indicative of functional or regulatory overlap between these pathways?  
As with UbcH8, it is clear that no other E3 can substitute for the broad effect of Herc5 in 
ISG15 conjugation however, it is not known whether Herc5 might also function in Ub 
conjugation.  There may be mechanistic or structural features of Herc5 that distinguish it 
from Ub HECT E3s, or Herc5 might simply preferentially recruit UbcH8 over other E2s.   
These unique problems make the ISG15 system of interest for addressing general 
mechanism and design of Ubl conjugation systems.  In addition, understanding the 
biochemistry of ISG15 conjugation may ultimately aid in the elucidation of the 
biochemical function of ISG15 conjugation and the basis of its antiviral activity. 
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Chapter 4:  The ISG15 Conjugation System Targets Newly Synthesized 
Proteins 
4.1 INTRODUCTION 
ISG15 is a 17 kD ubiquitin-like protein (Ubl) that is rapidly induced by type 1 
interferons (IFN-α and β).  Induction by interferon implied, over 20 years ago, that 
ISG15 was a component of the innate immune system (Farrell et al., 1979), however it 
has only been recently confirmed that ISG15 has anti-viral activity against several types 
of viruses, including Influenza, Sindbis, Herpes, HIV, and Ebolavirus (Hsiang et al., 
2009; Lenschow et al., 2007; Okumura et al., 2006; Okumura et al., 2008).  In addition, 
several viruses have evolved mechanisms for interfering with ISG15 function:  the NS1 
protein of Influenza B blocks ISG15 conjugation (Yuan and Krug, 2001), SARS 
coronavirus encodes an ISG15 deconjugating enzyme (Lindner et al., 2007), and the 
Vaccinia E3 protein binds to ISG15 and blocks its anti-viral activity (Guerra et al., 2008; 
Yuan and Krug, 2001).  The ability of ISG15 to be conjugated to other proteins has been 
shown in some cases to be essential for its anti-viral activity (Giannakopoulos et al., 
2009; Lai et al., 2009).  The biochemical function of ISG15 conjugation and the basis of 
the anti-viral activities of ISG15 conjugation remain unknown. 
While ISG15 is a very rapidly induced IFN-stimulated gene, conjugation does not 
become apparent until 18-24 hours after IFN stimulation, corresponding with the delayed 
induction of the ISG15 E1, E2, and E3 enzymes (Dastur et al., 2006).   The human ISG15 
E1 enzyme is Ube1L (Yuan and Krug, 2001) and the E2 enzyme is UbcH8/Ube2L6 (Kim 
et al., 2004; Zhao et al., 2004).  The major E3 for human ISG15 is Herc5, a HECT 
domain ligase that contains N-terminal RCC1 repeats (Dastur et al., 2006; Wong et al., 
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2006). Herc5 depletion results in a dramatic decrease in ISG15 conjugation, affecting 
conjugation to the vast majority of cellular target proteins, and co-expression of ISG15, 
Ube1L, UbcH8, and Herc5 in non-IFN-stimulated cells reconstitutes broad and robust 
ISG15 conjugation (Dastur et al., 2006).  Herc5 has also been shown to have anti-viral 
activity against influenza A virus (Zhao et al., 2009). EFP, a RING E3, has been reported 
to be an additional E3 for ISG15, however only a single target has been reported (Zou 
and Zhang, 2006). Therefore, while additional proteins may play a role in ISG15 
conjugation, Ube1L, UbcH8, and Herc5 represent the core IFN-induced components of 
this conjugation system in human cells.   
 Proteomics studies have identified over 300 cellular proteins that are targeted for 
ISGylation (Giannakopoulos et al., 2005; Wong et al., 2006; Zhao et al., 2005).  These 
targets were present in many cellular compartments and no functional classes of proteins 
were particularly overrepresented, although twelve IFN-induced human proteins were 
identified (Zhao et al., 2005).   A common structural or primary sequence element that 
confers ISG15 conjugation has not been identified, nor have poly-ISG15 chains been 
observed.  Importantly, only a small fraction of the pool of a given target protein is 
generally modified (Zhao et al., 2005).  These observations raise the following questions:  
1) how can a single ISG15 ligase be responsible for targeting such a large and diverse set 
of proteins, 2) what is the biochemical effect of ISG15 conjugation on target proteins, and 
3) how can modification of a small fraction of any individual target protein have a 
significant effect on the overall activity of that protein?    The findings presented here 
lead to a model that accounts for broad substrate targeting in the ISG15 system and 
provide a basis for understanding the anti-viral activity of ISG15 conjugation. 
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4.2 RESULTS 
4.2.1 The ISG15 system targets a broad range of proteins.   
ISG15 conjugation can be observed experimentally by treating HeLa cells with 
IFN-β, preparing total cell lysate 24-48 hours post-treatment, and immunoblotting with 
anti-ISG15 antibody (Figure 4.1A).  Surprisingly, when such lysates were immunoblotted 
with antibodies against previously identified target proteins it was difficult to observe 
their modification.   
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Figure 4.1: Detection of ISG15 conjugates in IFN-β treated HeLa cells. 
A) Total ISG15 conjugates in HeLa cells.  Cells were either untreated or treated with 
IFN-β for forty-eight hours.  Cell extracts were analyzed by SDS-PAGE and 
immunoblotting with anti-ISG15 antibody  
B) Modification of constitutively expressed target proteins.  Cells were treated and 
extracts analyzed as in (A), using the indicated antibodies.  Short (left) and long 
exposures (right) are shown for each immunoblot.    
C) ISG15 modification of p56, an interferon-induced protein.  Same as described in (A), 
with immunoblot analyzed with anti-p56 antibody.   
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 This is seen in Figure 4.1B for two such proteins, IQGAP1 and Ube1.  While 
modification of both proteins could be detected on very long exposures, modification of 
Hsc70 (Figure 4.1B) and four other constitutively expressed target proteins could not be 
detected (Table 4.1).  The success rate for validation of IFN-induced target proteins was 
higher, with three out of five targets confirmed, as shown for p56 (Figure 4.1C) and 
summarized in Table 4.1. As negative controls, five proteins not previously identified as 
targets of ISG15 modification were examined, and none of these were detectably 
modified in IFN-β-stimulated cells (Table 4.1). 
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Target protein 
Previously 
Identified 
Target? 
Interferon-
induced? 
Detectable 
ISGylation in 
IFN-treated 
HeLa cells? 
Detectable 
ISGylation in 4-
Plasmid 
Transfection? 
Ube1 yes no yes yes 
IQGAP1 yes no yes yes 
Hsc70 yes no no no 
Moesin yes no no no 
Tubulin yes no no no 
Matrin 3 yes no no no 
Enolase yes no no no 
          
MxA yes yes yes na 
RIG-I yes yes yes na 
p56 yes yes yes na 
PKR yes yes no na 
RIG-G yes yes no na 
OAS1 no yes no na 
PLSCR1  no yes no na 
          
E6AP no no no no 
hnRNPk no no no no 
Nucleophosmin no no no no 
Table 4.1: Summary of endogenously expressed target proteins. 
ISG15 conjugates can also be generating by expressing the core components of 
the conjugation system (ISG15 or FLAG-ISG15, Ube1L, UbcH8, and Herc5) by a four-
plasmid transfection of non-IFN-stimulated cells.  As seen in Figure 4.2 (top), robust 
ISG15 conjugation was observed in HEK293T cells subjected to this four-plasmid 
transfection.  However, it was again difficult to detect ISGylation of individual 
endogenously expressed target proteins, as shown for IQGAP1, Moesin, and Ube1 
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(Figure 4.2A), although, as in IFN-stimulated HeLa cells, a low level of modification of 
IQGAP1 and Ube1 could be detected on very long exposures (not shown).  Modification 
of only two of seven previously identified targets could be validated by this method 
(Table 4.2). 
To further investigate the problem of target protein validation, non-IFN-
stimulated cells (HEK293T) were transfected with plasmids expressing individual 
epitope-tagged target proteins, along with plasmids encoding the four core ISG15 
conjugation components (a five-plasmid transfection).   Surprisingly, in this scenario, 
ISG15 modification was detected for IQGAP1, Ube1, and Moesin (Figure 4.2B), as well 
as all other previously identified target proteins tested (Figure 4.3 and summarized in 
Table 4.2).   
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Figure 4.2: ISG15 conjugation to endogenously versus exogenously expressed target 
proteins.  
A) ISGylation of endogenously expressed target proteins.  HEK293T cells were either 
mock-transfected (lane 1), transfected with Ube1L, UbcH8, Herc5, and ISG15 (lane 2), 
or Ube1L, UbcH8, and Herc5 (lane 3). Cell extracts were prepared 48 hours post-
transfection and analyzed for ISG15 conjugation by immunoblotting using the indicated 
antibodies.  
B) ISGylation of exogenously expressed target proteins.  HEK293T cells were 
transfected with a plasmid expressing an epitope-tagged target protein (FLAG-IQGAP1 
in top two panels, V5-moesin, or V5-Ube1) either alone (lane 1), or combined with 
Ube1L, UbcH8, Herc5, and ISG15 (lane 2), or combined with Ube1l, UbcH8, and Herc5 
(lane 3). Cell extracts were prepared 48 hours post-transfection and analyzed by 
immunoblotting using the indicated antibodies.  
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Figure 4.3: ISGylation of additional exogenously expessed target proteins.   
HEK293T cells were transfected with a plasmid expressing an epitope-tagged target 
protein either alone (lane 1), or combined with Ube1L, UbcH8, Herc5, and ISG15 (lane 
2), or combined with Ube1l, UbcH8, and Herc5 (lane 3).  Cell extracts were prepared 48 
hours post-transfection and analyzed by immunoblotting using the indicated antibodies. 
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Figure 4.4: ISGylation of human proteins not previously identified as ISG15 targets. 
HEK293T cells were transfected with the indicated plasmids.  Cell extracts were 
prepared 48 hours post-transfection and analyzed by immunoblotting using the indicated 
antibodies. 
These results prompted us to assay, as presumptive negative controls, several 
epitope-tagged human proteins that had not been previously identified as ISG15 targets.  
Five out of seven of these were also found to be ISGylated, including E6AP, p53, Dlg, 
Herc4, and Herc6 (Figure 4.4 and Table 4.2).  Several non-human proteins were also 
assayed, including the E. coli β-galactosidase, Shigella flexneri OspG, Salmonella 
typhimurium SopA, the TAP epitope tag (two copies of the protein A sequence and the 
calmodulin binding protein), and two viral proteins (HPV18 L1 and HIV integrase).  All 
of these were modified when expressed along with the conjugation components (Figure 
4.5 and Table 4.2).  Three proteins were identified that were consistently not ISGylated in 
this assay system:  GFP, human Wbp2, and a 35 kD carboxy-terminal fragment of 
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paxillin.  We also confirmed that the nature of the epitope tag did not influence 
modification (see Figures 4.2 and 4.3 for modification of TAP-, HA-, and V5-Ube1, and 
Table 4.2 for others). 
 
 
Figure 4.5: ISGylation of foreign proteins. 
 
HEK293T cells were transfected with the indicated plasmids.  Cell extracts were 
prepared 48 hours post-transfection and analyzed by immunoblotting using the indicated 
antibodies. 
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Target Protein Previously Identified Target? 
Detectable ISGylation 
in 5-Plasmid 
Transfection? 
IQGAP1 (TAP,  FLAG) yes yes 
Moesin (V5) yes yes 
Ube1 (V5, TAP, HA) yes yes 
TrxR1 (V5) yes yes 
Ran (V5) yes yes 
Cofilin (FLAG) yes yes 
p56 (TAP) yes yes 
Hsc70 (TAP, Myc) yes yes 
MxA (FLAG) yes yes 
p53 (HA, TAP, FLAG) no yes 
E6AP (C-A mutant; TAP) no yes 
Herc6 (C-S mutant; HA, TAP) no yes 
Herc4 (TAP) no yes 
Dlg (FLAG) no yes 
Paxillin (C-term.; FLAG) no no 
Wbp2 (HA) no yes 
Shigella OSPG (TAP) na yes 
Salmonella  SopA (TAP)  na yes 
TAP epitope, no fusion na yes 
S. cerevisia Rsp5 (untagged)   na yes 
E. coli NeoR protein (TAP) na yes 
E. coli β-gal. (TAP, HA) na yes 
HPV16 L1 protein (untagged) na yes 
HPV18 L1 protein (V5) na yes 
HIV Integrase (TAP) na yes 
GFP na no 
Table 4.2: Summary of proteins expressed by plasmid transfection. 
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In an attempt to map a domain on a target protein that was recognized by the 
ISGylation enzymes, three non-overlapping fragments of IQGAP1 were assayed for 
modification (Figure 4.6A).  Surprisingly, all three fragments of the protein were 
ISGylated.  Similar results were seen with two non-overlapping fragments of MxA 
(Figure 4.6B), indicating that the ISGylation machinery does not recognize a single 
epitope even within an individual protein.  Together, these results suggested that, at least 
in the 5-plasmid transfection assay, the ISGylation machinery recognizes target proteins 
in a broad and relatively nonspecific manner. 
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Figure 4.6: ISGylation of non-overlapping target protein fragments. 
A) Schematic of IQGAP1, along with three non-overlapping fragments, A-C, with amino 
acid numbering shown (top).  Plasmids expressing TAP-tagged fragments A-C were 
transfected into HEK293T cells with Ube1L, UbcH8, Herc5, and with or without ISG15.  
Extracts were prepared and analyzed with anti-TAP antibody.   
B) Schematic of MxA, along with two non-overlapping fragments, A and B, with amino 
acid numbering shown (left).  Plasmids expressing TAP-tagged fragments A and B were 
transfected into HEK293T cells and analyzed as in (A) using anti-TAP antibody.   
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To address whether the broad target recognition in the five-plasmid transfection 
assay was related to overexpression of the transfected target proteins, we monitored, at 
several time points after transfection, the protein levels and modification of two 
exogenously expressed target proteins (TAP-Ube1 and TAP-IQGAP1) relative to the 
corresponding endogenously expressed proteins.  Figure 4.7 (left panels) shows the 
relative levels of exogenously and endogenously expressed proteins in the absence of 
ISG15 (expression of target protein with Ube1L, UbcH8, and Herc5, without ISG15), 
using an antibody that detects both proteins.  The exogenously expressed proteins could 
be detected by 6 hours post-transfection for both TAP-Ube1 and TAP-IQGAP1.  For 
Ube1, the levels of the exogenous protein did not exceed that of endogenous Ube1, even 
at 30 hours post-transfection, while for IQGAP1 the levels of exogenous protein were 
similar and perhaps slightly higher than endogenous IQGAP1 at 24 and 30 hours post-
transfection (correcting for the ~50% transfection efficiency).  However, at the 18-hour 
time point, when the exogenously expressed proteins were clearly less abundant than the 
endogenously expressed proteins, ISGylation of the exogenously expressed proteins was 
detected when the target protein was expressed with all four conjugation components 
(Figure 4A, middle panels).  In contrast, modification of the endogenous proteins was not 
detectable at any time point (Figure 4.7, right panels).  Therefore, the preferential 
modification of exogenously expressed proteins was not due to a higher steady state level 
of the exogenously expressed target proteins. 
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Figure 4.7: Time course of expression and ISGylation of exogenously versus 
endogenously expressed target proteins. 
 
Left panels: HEK293T cells were transfected with plasmids expressing either TAP-Ube1 
or TAP-IQGAP1 along with Ube1L, UbcH8, and Herc5 (3X). Cell extracts were 
prepared at the indicated time points after transfection and analyzed by immunoblotting 
with antibodies against Ube1 or IQGAP1 to compare exogenous and endogenous protein 
levels (left panels).  
Middle panels: HEK293T cells were transfected with TAP-Ube1 or TAP-IQGAP1 plus 
Ube1L, UbcH8, Herc5, and FLAG-ISG15 (4X).  Cell extracts were collected at the 
indicated time points and analyzed with an antibody against TAP to detect ISGylation of 
the exogenous targets.  Asterisks mark the earliest detectable conjugates to TAP-Ube1 
and TAP-IQGAP1. 
Right panels: HEK293T cells were transfected with Ube1L, UbcH8, Herc5, and FLAG-
ISG15 (4X, with no exogenous target protein), and extracts were analyzed for 
modification of endogenously expressed Ube1 or IQGAP1.     
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4.2.2 Newly synthesized proteins are targeted for ISGylation.  
To account for the preferential modification of exogenously expressed target 
proteins, we considered that in the five-plasmid transfection assay the entire pool of the 
target protein was synthesized in the same window of time that the ISG15 conjugation 
machinery was active.  In contrast, in all assays where endogenously expressed proteins 
were examined, only a fraction of the target protein was synthesized while the 
conjugation machinery was active (a function of the rate of synthesis of that protein).  
Also, in the five-plasmid transfections the mRNA levels encoding the exogenously 
expressed proteins were approximately 10-fold higher than the corresponding 
endogenously expressed mRNAs (based on three examples, Figure 4.8), suggesting that 
the exogenously expressed proteins, while not present at a higher steady-state level, were 
translated at a higher rate.  These distinctions suggested that ISG15 conjugation might be 
limited to the newly synthesized pool of any given target protein.  An additional 
observation consistent with this was the relatively high success rate for validation of IFN-
induced ISG15 targets (e.g., p56, MxA) in IFN-stimulated cells (see Table 4.1), where 
the entire pool of these proteins is, by definition, newly synthesized. 
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Figure 4.8: Exogenously expressed mRNAs are more abundant than the 
corresponding endogenously expressed mRNAs 
Total mRNA was isolated from untransfected HEK293T cells (-) or cells transfected with 
TAP-IQGAP1 (IQG1), TAP-Ube1 (Ube1), or TAP-53 (p53) expression plasmids for 24 
hours.  After DNase treatment, cDNA was prepared with and without reverse 
transcriptase.  RT-PCR reactions were performed using primer sets that detect both the 
endogenously and exogenously expressed mRNAs.  A GAPDH primer set was used as a 
control for equal RNA in the each set of samples and is shown for the IQGAP1-
transfected samples.  
We tested the hypothesis that ISGylation is limited to newly synthesized proteins 
in three ways.  In one approach (Figure 4.9A), an intracellular pool of a target protein 
was first established by plasmid transfection.  Twenty-four hours later, the ISG15 
conjugation machinery was expressed by a four-plasmid transfection, with or without co-
transfection of an siRNA targeting the mRNA encoding the plasmid-expressed target 
protein.  Extracts were prepared 22 hours after the second transfection, and the target 
protein was analyzed for ISGylation.  Our hypothesis predicted that if ISG15 
modification was dependent on protein synthesis, then siRNA-mediated destruction of 
the mRNA would result in a loss of ISGylation of the target protein.  That is, the pre-
existing pool of the target protein, synthesized in the first 24 hours, would not be 
modified.  In contrast, in the absence of a specific siRNA or in the presence of an off-
target siRNA, the target protein would continue to be synthesized and ISGylation would 
be observed.   
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Figure 4.9: Blocking synthesis of an exogenous target protein blocks its ISGylation. 
A) Schematic of experimental design.  A plasmid expressing an epitope-tagged target protein was 
transfected at time zero; target mRNA (red line) and target protein (dashed blue line) accumulated 
over the next 24 hours. Plasmids expressing Ube1L, UbcH8, Herc5, and FLAG-ISG15 were then 
transfected, either without or with an siRNA that recognized the target protein mRNA.  In the 
absence of the target siRNA (left), modification of the target protein was expected to occur as the 
ISG15 conjugation components (double green line) accumulated and the target protein continued 
to be synthesized.  In the presence of the target siRNA (right), target protein mRNA would be 
destroyed as the conjugation components are expressed, but previously synthesized protein persist 
as a function of their rate of destruction. 
B) TAP-IQGAP1 and TAP-p53 are long-lived proteins.  Plasmids expressing TAP-IQGAP1 or 
TAP-p53 were transfected into HEK293T cells and treated with cycloheximide (40 µg/ml) 24 hrs 
after transfection. Extracts were prepared immediately, or 3, 6, or 18 hrs. later.  Immunoblots 
with anti-TAP indicated that the protein levels did not decline more than 2-fold over 18 hrs.  
C) Knockdown of target protein mRNA blocks target protein modification. HEK293T cells were 
transfected with either TAP-IQGAP1 or TAP-p53, and transfected again 24 hours later with 
Ube1L, UbcH8, Herc5, and ISG15, without or with siRNAs against IQGAP1, p53, or an off-
target siRNA against hTfr (human transferrin receptor). Cell extracts were prepared 22 hrs after 
the second transfection and analyzed by immunoblotting with anti-TAP. 
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This experiment was dependent on the rate of degradation of the target protein, and for 
the targets analyzed, protein levels did not decline more than two-fold after siRNA 
transfection (Figure 4.9B).   Figure 4.9C shows the results for analysis of TAP-IQGAP1 
and TAP-p53.  ISGylation of both proteins was observed in the absence of any siRNA or 
in the presence of off-target siRNAs, but was greatly diminished in the presence of a 
specific siRNA.  These results were consistent with the hypothesis that a protein must be 
actively synthesized in order for it to be modified by ISG15. 
A pulse-labeling scheme was used to globally determine whether ISGylation was 
limited to proteins synthesized in the same window of time that the conjugation 
machinery is active.  In preliminary experiments, we determined that ISG15 conjugates 
became evident approximately 12 hours after a 4-plasmid transfection (FLAG-ISG15, 
Ube1L, UbcH8, and Herc5).  Therefore, HEK293T cells were transfected with the four 
plasmids, then pulse-labeled with 35S-labeled cysteine either before conjugation was 
occurring (6 hours post-transfection) or while conjugation was occurring (22 hours post-
transfection).   Total cell lysates were collected 24 hours post-transfection, and an anti-
FLAG immunoprecipitation was analyzed by SDS-PAGE and autoradiography.  Our 
hypothesis predicted that 35S-containing proteins labeled at the early time point would not 
be ISGylated, while proteins labeled at the late time point, while conjugation was 
occurring, would be susceptible to ISGylation.  A broad range of labeled proteins were 
conjugated to ISG15 in cells labeled at the 22 hour time point, while the pattern of 
labeled immunoprecipitated proteins from the early labeling period was only slightly 
above that seen in control untransfected cells (Figure 4.10B, compare lane 2 to lanes 1, 5, 
and 6).  The slight signal over background in the lanes corresponding to the early labeling 
period may be due to either a secondary mode of ISG15 conjugation (e.g., a minor Herc5-
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independent conjugation pathway), or due to turnover of the 35S-cysteine and re-
incorporation into newly translated proteins at later time points.  This experiment was 
also performed using a FLAG-ISG15 expression plasmid encoding an ISG15 mutant 
lacking the N-terminal ubiquitin-like domain (FLAG-ISG15-∆N), which is conjugated 
similarly to wild-type ISG15.  As above, 35S-labeled proteins were co-
immunoprecipitated with FLAG-ISG15-∆N when cells were labeled at the 22-hour time 
point, but not when cells were labeled at the 6-hour time point (Figure 4.10B, lanes 3 and 
4).  An anti-FLAG western blot of total extracts indicated that conjugation was robust in 
all samples expressing the conjugation components, regardless of the point at which the 
cells were labeled with 35S-cysteine (not shown). TCA precipitations of the extracts 
indicated that total protein labeling (dpm/µg of total protein) was similar among all 
samples (not shown).  These results were consistent with the notion that proteins are only 
subject to ISG15 conjugation if they are synthesized in the window of time that the 
conjugation machinery is active. 
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Figure 4.10: 35S-Cysteine Metabolic Labeling Demonstrates that Pre-Existing Pools 
of Cellular Proteins Are Not Subject to ISG15 Conjugation. 
A) Schematic of experimental design.  HEK293T cells were transfected either with Ube1L, 
UbcH8, and Herc5 (3X) or Ube1L, UbcH8, Herc5, and either FLAG-ISG15 C78S or FLAG-∆N-
ISG15 (4X). Cells were labeled for two hours with 35S -cysteine beginning either 6 or 22 hrs post-
transfection (grey boxes), corresponding to periods before or during which ISG15 conjugation 
was occurring (approximate time course of ISG15 conjugation indicated by dashed line).  
B) Immunoprecipitation of labeled cellular proteins conjugated to ISG15.  ISG15 conjugates were 
immunoprecipitated with anti-FLAG beads, 35S-labeled cellular proteins that were conjugated to 
ISG15 were analyzed by SDS-PAGE and autoradiography.  Plasmids transfected are indicated in 
the figure.  Early (E) refers to 35S-labeling 6 hours post-transfection, while late (L) refers to 35S-
labeling 22 hours post-transfection. 
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A third assay utilized puromycin, which inhibits translation by covalent 
incorporation into the carboxy-terminal end of nascent polypeptide chains. Our 
hypothesis predicted that puromycin treatment of cells that were actively conjugating 
ISG15 would lead to the generation of polypeptides that contained both ISG15 and 
puromycin.  Cells were therefore subjected to a four-plasmid transfection (FLAG-ISG15, 
Ube1L, UbcH8, Herc5) or a 3-plasmid transfections that omitted an individual enzyme 
component.   Twenty-four hours later, cells were treated with puromycin for 2 minutes 
before preparation of cell extracts.  ISG15 conjugates were immunoprecipitated with anti-
FLAG antibody and then analyzed by immunoblotting with anti-puromycin antibody.  As 
shown in Figure 4.11, cells expressing all four conjugation components contained a broad 
range of polypeptides that were modified with both ISG15 and puromycin.  Such 
polypeptides were not detected in cells that were not treated with puromycin.  Cells 
lacking Ube1L, UbcH8, or Herc5 had a very small amount of conjugates, corresponding 
to the low basal expression of these enzymes in non-IFN-treated cells (not shown).  
These results were therefore consistent with the model that newly synthesized proteins 
are targeted for ISGylation. 
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Figure 4.11: Cells treated with puromycin contain polypeptides that are modified 
with both puromycin and ISG15.  
HEK293T cells were transfected with either four plasmids (FLAG-ISG15, Ube1L, 
UbcH8, and Herc5) or three plasmids (same, without either Ube1L, UbcH8, or Herc5).  
Twenty-four hours post-transfection, cells were harvested or treated with 1 mM 
puromycin for two minutes and cell extracts were prepared.  Five percent of the extracts 
were immunoblotted with anti-puromycin (bottom).  The remaining extracts were 
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-puromycin 
antibody (top).   
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4.2.3 Herc5 is associated with polyribosomes.   
The ISGylation of newly synthesized proteins suggested that modification might 
occur co-translationally.  We therefore determined whether endogenously expressed 
Herc5 co-fractionated with ribosomes and/or polysomes.  HeLa cells were treated with 
IFN-β for 24 hours and cell extracts were fractionated by sucrose gradient sedimentation.  
Ribosome- and polysome-containing fractions, including the 40S and 60S ribosomal 
subunits, were identified by characteristic absorbance profiles at 254 nm and confirmed 
by immunoblotting with anti-ribosomal subunit antibodies.  As shown in Figure 4.12A, 
the vast majority of Herc5 protein was within the polysome-containing fractions.  Herc5 
co-fractionated with 80S ribosomes when extracts were treated with RNase (Figure 
4.12B), which destroys the polysomes and leads to a large increase in the amount of 80S 
ribosomes.  This suggested that Herc5 was associated with polysomes via ribosomes, 
rather than mRNA.  Consistent with this, Herc5 co-fractionated with 60S ribosomes when 
extracts were treated with EDTA (Figure 4.12C), which dissociates polysomes and 80S 
ribosomes into 40S and 60S subunits.  EDTA also releases nascent polypeptides from the 
60S subunit (Ullers et al., 2004; Valent et al., 1997), suggesting that Herc5 was unlikely 
to be tethered to ribosomes via nascent polypeptides.  Herc4 is a HECT domain ligase 
that has 57% primary sequence similarity to Herc5 (Hochrainer et al., 2005), but it is not 
IFN-induced and does not function in ISG15 conjugation.   Neither endogenously 
expressed Herc4 or another unrelated HECT E3, E6AP/Ube3A, co-fractionated with 
polysomes (Figure 4.12A). 
95 
 
 
Figure 4.12: Herc5 fractionates with polysomes. 
A) Herc5 fractionates with polysomes in HeLa cell extracts. HeLa cells were treated with 
IFN-β for 24 hours and subjected to polysome analysis (Methods). The A254 profile 
shows the positions of the 40S, 60S, 80S, and polysome fractions. Fractions were 
analyzed by immunoblotting with the indicated antibodies. 
B) Herc5 fractionates with the 80S ribosomes after RNase treatment. HeLa cells were 
treated and analyzed as described in (A), however RNase was added to the cell lysate 
after harvest. Fractions were analyzed by immunoblotting with anti-Herc5 antibody.   
C) Herc5 fractionates with the 60S ribosomal subunit after EDTA treatment.  HeLa cells 
were treated and analyzed as described in (A), with addition of EDTA to the cell lysate 
after harvest. Fractions were analyzed by immunoblotting with anti-Herc5 antibody.   
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Herc5 contains four well-defined RCC repeats between residues 150 and 370 and 
three less well conserved repeats in the first 150 amino acids.  Deletion of this entire 
region (∆RCC) abrogates ISGylation of target proteins (not shown), as does deletion of 
amino acids 2-100 (∆100), however both proteins retain catalytic activity based on auto-
conjugation activity (Figure 4.13A).  Full-length HA-tagged Herc5 expressed by 
transfection was present in the polysome fractions (Figure 4.13B), although it was present 
in earlier ribosome-containing fractions of the gradient, probably due to the approximate 
5-fold overexpression of HA-Herc5 relative to the IFN-induced levels of Herc5 in HeLa 
cells.  In contrast, both the HA-∆RCC and HA-∆100 Herc5 proteins were present almost 
exclusively in the earliest fractions of the gradient.  Therefore, the RCC1 repeat region of 
Herc5 is essential for both ISGylation and polysome association.   
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Figure 4.13: The RCC1 repeats are required for ISGylation of target proteins and co-
sedimentation with polysomes. 
A) Herc5-∆RCC and Herc5-∆100 cannot conjugate ISG15 to target proteins.  Plasmids 
expressing FLAG-p56 were transfected into HEK293T cells along with plasmids expressing 
Ube1L, UbcH8, ISG15, and NTAP-Herc5 or the indicated Herc5 mutants.  Cell extracts were 
prepared 48 hours post-transfection and ISGylation of p56 was determined by immunoblotting 
with anti-FLAG antibody.  The asterisk marks ISG15 modification of p56 due to endogenous 
Herc5.  
B) HEK293T cells were transfected with HA-Herc5, HA-∆RCC, or HA-∆100 expressing 
plasmids and harvested after 24 hours.  Cell extracts were fractionated as above and analyzed by 
anti-HA immunoblotting.   
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4.3 DISCUSSION 
We have shown here that the range of ISG15 target proteins is extremely broad, 
that newly synthesized proteins are the targets of ISGylation, and that Herc5 is associated 
with the translational machinery.  These findings suggest that the ISG15 system is 
designed to target newly synthesized proteins, with limited target protein selectivity. 
Herc5 protein in extracts of interferon-stimulated HeLa cells co-fractionated with 
polysomes, and further analyses suggested that it is associated with a core component of 
the 60S ribosomal subunit.  As the exit tunnel for nascent polypeptides is on the 60S 
subunit (Kramer et al., 2009), an attractive model is that Herc5 modifies newly 
synthesized polypeptides co-translationally, as they emerge from the exit tunnel.  
Interestingly, other protein modification enzymes have been identified that are ribosome-
associated and function near the exit tunnel, including methionine isopeptidase (Raue et 
al., 2007; Vetro and Chang, 2002), N-terminal acetyltransferases (Green et al., 1978; 
Pestana and Pitot, 1975), and chaperones that aid in co-translational folding of proteins 
(Kramer et al., 2009).  Polysome association of Herc5 suggests that the inclusion of a 
translation system will be a requirement for reconstitution of in vitro ISGylation, which 
in turn is likely to be required for a direct test of the co-translational model. Also, it is 
important to note that while the range of ISG15 target proteins appears extremely broad, 
not all newly synthesized proteins were ISGylated in our assays. Factors that might 
influence susceptibility to modification include rates of translation, co-translational 
folding rates, and the sequence or secondary structure context of lysine acceptors. 
The biochemical function of ISG15 conjugation remains unknown.  The two most 
general possibilities are that ISG15 signals to another protein or protein complex (e.g., in 
the way that ubiquitin signals to the proteasome), or it simply disrupts the function of 
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proteins to which it is conjugated.  There is evidence to support the latter in studies that 
have examined individual target proteins (Jeon et al., 2009; Zou et al., 2005), and this 
may also be inferred by ISG15 protein sequence comparisons between mammalian 
species.  Unlike ubiquitin and most other Ubls, ISG15 protein sequences are very 
divergent.  Only 72 out of 157 residues (46%) are identical between the human, mouse, 
rat, dog, cow, and sheep ISG15 protein sequences.  We suggest that these divergent 
mammalian ISG15 proteins are unlikely to have retained a common signaling function, 
and that the similarity retained reflects that which is required for maintaining the 
ubiquitin-like folds of ISG15 and for productive interaction with the conjugation 
enzymes. We therefore suggest that the function of ISG15 is to generally disrupt target 
protein function, and the functions of viral proteins, in particular.   
But how could ISG15 conjugation be an effective defense against viruses when, 
even among the newly synthesized pool of a target protein, ISGylation is so inefficient?  
The answer may lay in the fact that structural proteins are generally among the most 
actively expressed of viral proteins, and capsid and nucleocapsid proteins must assemble 
into precise repeating geometric configurations to form infectious virus particles.  
Therefore, ISGylation of a small fraction of the total pool of a viral structural protein 
might have a strong dominant-negative effect on virus assembly or infectivity. 
Interestingly, a recent study identified a dominant-negative HIV1 gag protein that 
inhibited HIV1 infectivity (IC50) at a ratio of 3-4% mutant to wild-type protein (Lee et 
al., 2009).  Finally, the low efficiency of ISGylation may be tuned to minimize the 
collateral damage to newly synthesized cellular proteins.  While this is a highly 
speculative model, the central experimental findings presented here – that ISG15 is 
broadly targeted to newly synthesized proteins - lead to testable hypotheses for the 
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identity of the biologically relevant targets of ISGylation in the innate immune response 
and the biochemical function of ISGylation. 
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Chapter 5: Implications for the anti-viral function of ISG15 
5.1 INTRODUCTION 
ISG15 is an interferon-induced and anti-viral ubiquitin-like protein (Ubl) (Farrell 
et al., 1979; Harty et al., 2009).  The human ISG15 E1 enzyme is Ube1L (Yuan and 
Krug, 2001) and the E2 enzyme is UbcH8/Ube2L6 (Kim et al., 2004; Zhao et al., 2004).  
Herc5, the major E3 enzyme for ISG15, mediates the ISGylation of over 300 proteins in 
interferon-stimulated cells (Giannakopoulos et al., 2005; Wong et al., 2006; Zhao et al., 
2005).  In addressing this broad substrate selectivity of Herc5, we found that:  1) the 
range of substrates extends even further and includes many exogenously expressed 
foreign proteins, 2) ISG15 conjugation is restricted to newly synthesized pools of 
proteins, and 3) Herc5 is physically associated with polyribosomes (Durfee, In press).  
These results lead to a model for ISGylation in which Herc5 broadly modifies newly 
synthesized proteins in a co-translational manner.   
Only modest progress has been made on determining the biochemical function of 
ISG15 conjugation.  Currently, it is not possible to easily generate purified ISGylated 
target proteins because a complete in vitro ISGylation system has not yet been 
established.  There are a few studies which have used cell-based approaches to examine 
ISG15 function:  1) ISGylated Ubc13 was shown to be defective for ubiquitin thioester 
formation (Takeuchi and Yokosawa, 2005; Zou et al., 2005), and 2) the ISGylation of 
filamin B was shown to lead to release of RAC1, MEKK1, and MKK4 from the scaffold, 
preventing JNK activation (Jeon et al., 2008).  These studies suggest that ISG15 non-
specifically disrupts the function of its target proteins by physical occlusion or 
obstruction.  One major issue with these studies is only a very small fraction of the total 
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pool of any target protein is modified with ISG15 and therefore, it is unclear how 
modification of a small fraction of any individual target protein might have a significant 
effect on the overall activity of that protein.     
Type 1 IFNs are secreted by virus-infected cells to establish an anti-viral state in 
uninfected surrounding cells (Samuel, 2001).  As these cells are likely to be the next sites 
of virus infection, newly synthesized viral proteins may be the targets of the ISGylation 
system.  In support of viral protein ISGylation, the influenza A viral protein, NS1, was 
recently shown to conjugated with ISG15 (Zhao et al., 2009).  As with host cellular 
proteins, there is still the question of how modification of a small fraction of a viral 
protein could have a significant anti-viral effect.  The answer may lay in the fact that 
structural proteins must often assemble into precise repeating geometric configurations to 
form infectious virus particles (e.g., capsid proteins).  
Human papillomavirus (HPV) is a non-enveloped icosahedral virus encapsidating 
an 8kb circular, double-stranded DNA.  Papillomavirus virions are composed of 360 
molecules of L1 (major capsid protein) and up to 72 molecules of L2 (minor capsid 
protein) (Buck et al., 2008).  L1 and L2 assemble into virions and undergo a process by 
which inter-L1 disulfide bonds form and stabilize the virion (Buck et al., 2005b).  During 
the maturation process the virions decrease in size to approximately 55 nm.  HPV virion 
assembly has been well studied and there are established protocols for the production of 
pseudovirions (PsV) (Buck et al., 2005a).  HPV PsV are similar to HPV virions, but 
instead of encapsidating the HPV genome, any double-stranded circular DNA ~8kb can 
be packaged.  We therefore employed an HPV pseudovirus (PsV) system to determine if 
ISGylation had an effect on infectivity.  The findings presented here provide a proof of 
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principle that low-level ISGylation of a virus structural protein can have dominant 
negative effects on virus infectivity. 
5.2 RESULTS 
5.2.1 ISG15 modification of HPV16 L1. 
We first determined if HPV16 capsid proteins, L1 and L2, were modified by co-
transfection of a plasmid expressing L1 and L2 (p16shell) with the ISGylation 
components.  Figure 5.1 shows that HPV16 L1 is modified with ISG15.  Currently, the 
status of L2 ISGylation is unknown.  We have been testing multiple antibodies and have 
not achieved clear results yet.  Next, we identified the ISG15 conjugation sites on the 
HPV16 L1 protein.  293TT cells were transfected as in Figure 5.1.  The HPV16 L1-
ISG15 conjugates were purified by immunoprecipitation with anti-HPV16 L1.  Mass 
spectrometry analysis identified two lysines residues that were conjugated with ISG15: 
lysine 64 and lysine 309.  These lysines are located in the BC-loop region and between 
the G1 and G2 β-strands, respectively (Chen et al., 2000).   
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Figure 5.1: ISGylation of HPV16 L1. 
293TT cells were co-transfected with p16shell, alone, or with plasmids expressing 
ISG15, Ube1L, UbcH8, and Herc5 (4X) or this set of plasmids without ISG15 (3X). Cells 
extracts were analyzed by SDS-PAGE and immunoblotting with anti-L1 antibody. 
 
5.2.2 HPV16 Pseudovirus System 
We therefore employed an HPV pseudovirus (PsV) system to measure the effect 
of ISGylation on infectivity (Buck et al., 2005a).  When L1 and L2 are expressed in the 
presence of a ~8 kbp GFP expression plasmid, the plasmid is packaged as if it were viral 
genomic DNA; these PsV can then be isolated on velocity-density gradients and their 
infectivity measured by quantitating the delivery of the GFP reporter plasmid to naive 
cells (Figure 5.2).  HPV16 pseudoviruses were generated in 293TT cells in which ISG15 
conjugation was either occurring (co-transfection of ISG15 and E1, E2, E3 enzymes) or 
not occurring (co-transfection of ISG15 and inactive mutant forms of the E1, E2, and E3 
enzymes).   
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Figure 5.2: Schematic of HPV PsV Experimental Design. 
Initially, HPV16 pseudoviruses were generated in 293TT cells in which ISG15 
conjugation was not occurring.    After ultracentrifugation through the Optiprep gradient, 
twelve fractions were obtained and analyzed for the presence of assembled PsV at the 
expected gradient fractions.  Previous reports suggested that large amounts of properly 
assembled PsV would migrate to fractions five through eight; also known as the peak 
PsV fractions (Buck et al., 2004).  This was confirmed by transmission electron 
microscopy of these fractions (Figure 5.3A) as well as by determination of the fraction 
infectivity by FACS analysis (Figure 5.3B). 
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Figure 5.3: Confirmation of properly assembled HPV PsV. 
A) Transmission electron microscopy (TEM) of HPV16 PsV.  HPV16 PsV were isolated 
from an Optiprep gradient, absorbed to carbon-coated copper grids, and stained with 1% 
uranyl acetate before viewing.      
B) Fractions 5-8 contain pronounced amounts of HPV16 PsV.  Equal volumes of HPV16 
PsV fractions obtained from Optiprep gradients were added to 293T cells.  Sixty hours 
post-infection, GFP-positive cells were quantitated by FACS analysis.   
 
5.2.3 The effect of HPV16 L1 ISGylation on PsV Infectivity. 
HPV pseudovirions were generated in the presence of either a wild-type 4X or 
mutant 4X.  Peak PsV fractions (fractions 5-8) from the Optiprep gradient were pooled 
for each and used to determine the ISGylation status of L1 as well as the infectivity.  In 
the ISGylated PsV fractions, approximately 10% of the total L1 protein was ISGylated 
(Figure 5.4A).  The total amount of L1 protein in ISGylated PsV fractions was 
approximately 30% less than in the control PsV fractions.  Together, these observations 
indicated that ISGylated L1 was incorporated into PsV particles, but that the overall yield 
of PsV was decreased.  To examine the infectivity of ISGylated and non-ISGylated PsV, 
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the peak gradient fractions were added to the culture media of 293T cells, followed by 
quantitation of GFP-positive cells by FACS analysis.  Without normalization for total L1 
concentration, the infectivity of ISGylated PsV was decreased approximately 80% 
relative to the non-ISGylated PsV in three independent experiments (Figure 5.4B).  With 
normalization, the infectivity of ISGylated PsV was approximately 70% lower than non-
ISGylated PsV (Figure 5.4B).  These results establish that low-level ISGylation of a viral 
structural protein can have a dominant-negative effect on virus infectivity.    
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Figure 5.4: Low-level ISGylation of HPV16 L1 has a dominant-negative effect of 
virus infectivity. 
A) ISGylated HPV16 L1 is detected in fractions containing HPV Pseudovirus.  Equal 
volumes of PsV-containing fractions, prepared in cell expressing active ISGylation 
enzymes (WT) or inactive mutants (Mut.), were separated by SDS-PAGE and 
immunoblotted with anti-L1 antibody.  
B) ISGylation of HPV16 L1 decreases the infectivity of HPV Pseudovirus.   293T cells 
were infected with equal volumes PsV from the fractions shown in Figure 7B, formed 
either in the absence (PsV) or presence (PsV + ISG15) of the ISG15 conjugation system.  
GFP-positive cells were counted 60 hours post-infection by FACS.  The infectivity of 
wild type PsV was set to 100%.   Results are presented both without (middle) and with 
(right) normalization for total L1 protein concentration. Error bars indicate standard error 
of the mean of three independent experiments performed in triplicate.  
5.3 DISCUSSION 
The findings presented here have implications for the identity of the biologically 
relevant targets of ISG15.  Interferon-stimulated cells are primed to defend against an 
impending viral infection, which suggests that newly translated viral proteins might be 
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biologically relevant targets of the ISG15 system.  The low degree of target protein 
selectivity of the ISG15 system is consistent with the requirement that the innate immune 
response protect cells against a wide range of pathogens.  We previously proposed a 
model where Herc5 modifies newly synthesized polypeptides co-translationally (Durfee, 
In press).  An implication of this model is that modification of cellular target proteins 
may be simply collateral damage in the attempt to target viral proteins.   This, in turn, 
may be tied to the observation that ISGylation is relatively inefficient:  an inefficient 
ISGylation system might protect against excessive damage to cellular proteins, while at 
the same time still be an effective anti-viral due to dominant-negative effects on 
abundantly expressed virus structural proteins (Figure 5.5). 
 
Figure 5.5: Model for the anti-viral function of ISG15 conjugation. 
The HPV pseudovirus system provides a proof of principle that low-level 
ISGylation of a virus structural protein can have dominant negative effects on virus 
infectivity.  The precise step in the infectivity of HPV pseudoviruses that is affected by 
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ISGylation of HPV capsids is not yet known, but could range from receptor recognition, 
to a defect in endocytosis or release from endocytic compartments, to the delivery of the 
packaged DNA to the nucleus.  The lysines identified by the mass spectrometry do not 
correspond to lysine residues with previously published roles in HPV capsid formation or 
infection (Bishop et al., 2007; Knappe et al., 2007), but not all thirty-four lysines in 
HPV16 L1 have been characterized.   
The effect of type 1 interferons on HPV replication is known to be complex 
(Beglin et al., 2009), however multiple studies have indicated that HPVs interfere with 
expression and/or function of components of the interferon response (Barnard and 
McMillan, 1999; Chang and Laimins, 2000; Nees et al., 2001; Ronco et al., 1998).  In 
addition, topical IFN-α is an approved treatment for certain HPV lesions (Slade et al., 
1998).  The results presented here warrant an examination of the role of the ISG15 
system in the response of HPV lesions to type 1 IFNs and, more broadly, of the effect on 
ISG15 on proteins of many other classes of viruses.  For example, pseudovirion systems 
have been established for many other viruses.  These systems can be used to examine if 
ISG15 disrupts virion formation of viruses besides HPV. 
In addition to virion assembly, ISG15 may disrupt the function of other types of 
viral proteins that multimerize.  HIV Rev is a good candidate as it oligomerizes to form a 
complex that transports viral mRNAs out of the nucleus (Dimattia et al., 2010).  A recent 
example of non-structural viral protein ISGylation is the modification of the NS1A 
protein of H1N1 influenza A/WSN/33 (WSN) virus (Zhao et al., 2009).  Zhao et al. 
demonstrated that approximately 5% of NS1A is ISGylated and mutation of one lysine 
residue, K41R, of NS1A led to a approximately 90% decrease in this ISGylation.  In 
addition, this mutation in NS1A was shown to be important for inhibition of viral 
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replication.  These results are another example of inhibition of viral replication by low-
level ISGylation of a viral protein.  The mechanism behind this inhibition is unknown. 
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Chapter 6:  Future Directions 
 
My thesis work has addressed two aspects of the human ISG15 conjugation 
system: 1) the specificity of the Ube1L-UbcH8 interaction and 2), the basis of substrate 
recognition by Herc5.  I have shown that interactions between the UFD of Ube1L and the 
α1-helix and β1−β2 region within UbcH8 mediate the specific selection of UbcH8 by 
Ube1L.  In addition, I have demonstrated that UbcH8 is unlikely to function as a Ub E2 
in most cell lines.  Based on the Herc5 work, I have proposed a model for ISGylation in 
which Herc5 broadly modifies newly synthesized proteins in a co-translational manner 
and suggested that, in the context of an interferon-stimulated cell, newly translated viral 
proteins may be primary targets of ISG15.  Consistent with this, I have shown that 
ISGylation of the human papillomavirus (HPV) L1 capsid protein has a dominant-
inhibitory effect on the infectivity of HPV16 pseudoviruses. These discoveries have 
greatly increased our understanding of the mechanism of ISG15 conjugation and raised 
many new questions regarding specificity within the ISG15 pathway, the mechanism for 
modification of newly synthesized proteins, and the dominant-negative inhibition of viral 
proteins.  
6.1: SPECIFICITY WITHIN THE ISG15 PATHWAY  
There are features of the ISG15 pathway that more closely resemble features of 
the Ub system than other Ubl systems.  For example, human Ube1L is the most closely 
related E1 enzyme to human Ube1 (E1Ub), and ISG15 is the only Ubl where the last six 
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residues of the protein (LRLRGG) are identical to that of Ub.  In addition, UbcH8 was 
initially reported to be an E2 for the Ub pathway.  Furthermore, Herc5 is the only HECT 
E3 enzyme known to function with a Ubl, rather than Ub.  While my work has identified 
the basis for specific recruitment of UbcH8 by Ube1L, several questions remain.   
Ube1L activates only ISG15 and Ube1 activates only Ub, but the basis for this 
specificity is unknown.  The E1 enzymes for Nedd8 and SUMO do not charge Ub due to 
specific C-terminal residues in Ub that differ from those in their Ubls (Schulman and 
Harper, 2009).  These residues are identical between ISG15 and Ub and therefore, it is 
unclear what restricts Ube1L from charging Ub.  A recent structure of Uba1 (yeast E1Ub) 
with Ub might shed some light on this question.  Lee et al. identified residues within 
three interfaces responsible for the Ub-Uba1 interaction, including the C-terminal 
LRLRGG residues (Lee and Schindelin, 2008).  Many of these residues are not conserved 
in Ube1L and the C-terminal half of ISG15.  For example, hydrophobic residues in the 
adenylation domain of Uba1 interact with the canonical hydrophobic patch of Ub, but 
both ISG15 and Ube1L lack these types of residues in the corresponding regions.   
While it has been established that no other E3 can substitute for Herc5 in the 
broad conjugation of ISG15 (Dastur et al., 2006; Dastur, 2007), it is possible that Herc5 
participates in ubiquitination, or even further, catalyzes a ubiquitination event required 
for ISGylation.  HECT E3 ligases are capable of autoconjugating Ub, but this has never 
been observed by western blot analysis of exogenously expressed Herc5 (Dastur, 2007).  
In contrast, Herc5 autoISGylation is easily detected when it is expressed with the ISG15 
conjugation machinery.  Therefore, there would appear to be mechanistic or structural 
features of Herc5 that distinguish it from Ub HECT E3s, or Herc5 might simply 
preferentially recruit UbcH8 over other E2s.  In vitro, the Ub HECT E3s RSP5 and E6AP 
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can be forced to receive ISG15 from UbcH8 which suggests the Herc5-E2 interaction 
may be important for maintaining pathway specificity (Zhao et al., 2004).   
In addition to Herc5, there are many questions surrounding the role of Herc6 in 
the ISG15 pathway.  Previous results have shown that human Herc6 is, at best, a minor 
E3 ligase for ISG15 (Dastur et al., 2006; Dastur, 2007).  It is possible that Herc6 has a 
limited number of target proteins or that Herc6 may participate in ubiquitination, 
although this has never been observed in vivo.  Understanding the role of Herc6 is further 
complicated by the fact that rodents lack a direct equivalent to Herc5 and instead have 
only Herc6.  Furthermore, recent results suggest mouse Herc6 can support broad 
ISGylation (Versteeg et al., 2010).  Mouse Herc6 shares a similar domain organization 
and is interferon-induced like human Herc5 and Herc6, however it shares more identity 
with human Herc6 than Herc5.  It is unclear why mouse Herc6 supports ISGylation, but 
not human Herc6.  We are currently testing human and mouse Herc6 to see if they 
associate with polysome fractions in a manner similar to that of Herc5.  Additionally, we 
need to examine these three enzymes more closely to identify determinants that prevent 
human Herc6 from functioning like mouse Herc6 and human Herc5.            
6.2: MECHANISM FOR MODIFICATION OF NEWLY SYNTHESIZED PROTEINS 
I have shown that Herc5 co-fractionates with polysomes and loss of the N-
terminal RCC repeats of Herc5 shifts it out of the polysomes.  Using RNase and EDTA 
treatments, I have demonstrated that Herc5 is not associated with polysomes via mRNA 
or nascent chains.  Instead, these treatments suggest Herc5 is associated with a core 
component of the 60S ribosomal subunit.  As the exit tunnel for nascent polypeptides is 
on the 60S subunit (Kramer et al., 2009), an attractive model is that Herc5 modifies 
newly synthesized polypeptides co-translationally, as they emerge from the exit tunnel.  
115 
 
Therefore, it is important to determine how Herc5 interacts with the ribosome.  The 
eukaryotic exit tunnel consists primarily of rRNA in complex with the ribosomal proteins 
L4, L17, L25, and L39 (nearest to the exit) (Bhushan et al., 2010).  One protein in 
particular, L25, is of interest because it has been shown to act as a docking protein for 
many proteins which act on nascent chains (Kramer et al., 2009).  While Herc5 may 
associate directly with a protein such as L25, it is also possible that the interaction is 
mediated by another ribosomal associated protein or that Herc5 may bind rRNA.  We 
initially attempted to use the yeast system to address the interaction because of the well 
characterized ribosomal mutant strains available.  Unfortunately, Herc5 did not associate 
with polysomes in yeast.  This was not entirely unexpected as yeast lack the ISG15 
pathway.  Currently, we are exploring the Herc5-ribosome interaction using 
immunoprecipitation (IP) techniques in conjunction with crosslinkers to stably link Herc5 
to the ribosome before IP.  
While I have shown that ISG15 modification occurs on newly synthesized 
proteins and that Herc5 associates with the ribosome, I have yet to determine if 
modification occurs co-translationally.  One way to address this question is to isolate 
ribosomal bound nascent chains and examine them for ISG15 modification.  Our current 
approach involves large-scale isolation of cycloheximide-treated ribosomes from 
mammalian cells transfected with the ISG15 components.  The low level of nascent 
chains coupled with the inefficiency of ISGylation has precluded a definitive answer so 
far.  A complete in vitro system would be helpful in testing this model because it would 
allow us to examine modification of a single, well-modified target protein under variable 
conditions. 
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Another interesting question involves the factors influencing ISG15 modification 
of newly synthesized proteins.  It is important to note that although the list of ISG15 
target proteins appears extremely broad, not all newly synthesized proteins were 
ISGylated.  GFP, human Wbp2, and a fragment of paxillin were consistently not 
ISGylated in our assay system.  In addition, examination of the modification sites of a 
limited number of ISGylated proteins suggests there are preferential modification sites 
within target proteins.  Ubc13 is ISGylated only at K92, but contains eight other lysines, 
while mass spectrometry results for HPV16 L1 identified only two modification sites 
(K64 and K309) out of a potential thirty-four lysines.  Identifying modification sites on 
additional target proteins would be helpful in determining if sequence or secondary 
structure context are factors in the selection of lysine acceptors.  In addition, ISGylation 
might be influenced by translation rates or co-translation folding.  In the future, we would 
like to see if altering the rate of translation alters the level of ISGylation.  One option 
might be to stall translation by deleting the termination codon of a gene.  Alternatively, 
larger proteins might be preferentially modified due to slow translating regions present to 
facilitate co-translational folding.  Clearly, there are many potential factors to be 
explored.    
Determining the mechanism for the modification of newly synthesized proteins is 
complicated by the fact that we are unable to reconstitute an in vitro ISGylation system. 
We can generate thioester formation between UbcH8 and ISG15 however, even with the 
addition of purified Herc5, we have been unable to transfer ISG15 from UbcH8 to Herc5 
and therefore we have been unable to re-create ISGylation of target proteins.  It has been 
unclear if purified Herc5 is inactive or if an additional factor(s) is required to support 
ISGylation.  Polysome association of Herc5 suggests that the inclusion of a translation 
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system may be a requirement for reconstitution of in vitro ISGylation.  We are in the 
process of examining rabbit reticulocyte lysate (RRL) as a possible in vitro translation 
system however, it is unknown if Herc5 can associate with rabbit ribosomal proteins.  In 
addition, we are developing an in vitro translation system using polysomes isolated from 
mammalian cell lysate.  An in vitro system would be useful not only for examining E3 
ligase specificity as discussed above, but also for testing the ISG15 co-translational 
modification model and examining factors influencing modification.   
  6.4: DOMINANT-NEGATIVE INHIBITION OF VIRAL PROTEINS 
I have shown that the human papillomavirus (HPV) L1 capsid protein can be 
ISGylated and although only a small fraction of L1 is modified, there is a significant 
decrease in the infectivity of ISGylated HPV pseudovirus (PsV).  These results raise two 
major questions: 1) what is the precise step in the infectivity of HPV PsV that is affected 
by ISGylation of HPV capsids, and 2) is the ISG15 mediated decrease in infectivity 
observable in vivo?  The decrease in infectivity could be stem from issues with DNA 
packaging or receptor recognition, to a defect in endocytosis or release from endocytic 
compartments, to the delivery of the packaged DNA to the nucleus.  Preliminary 
experiments where ISG15 was removed from mature PsV showed these PsV had the 
same decrease in infectivity as mature PsV with ISG15.  This suggests ISG15 somehow 
disrupted the PsV structure, but was not required once that alteration occurs.  Observing 
the effect of ISG15 on HPV in vivo is much more complicated due to the requirement of 
differentiating epithelial cells for the life cycle of HPV.  Raft tissue culture systems for 
HPV exist, however issues with transfection efficiency, the interferon response, and the 
long length of time required for differentiation would need to be addressed.   
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Alternatively, it will be important to test other viral structural and non-structural 
proteins to see if ISG15 mediates a dominant-negative effect similar to that seen in the 
HPV system.  For example, a pseudovirion system has been established for murine 
leukemia virus (MLV).  Similar to the HPV system, infectious MLV PsV can be 
generated by packaging a GFP reporter plasmid.  Pseudovirion systems similar to MLV 
exist for HIV and can be examined as well.  In addition to virion assembly, ISG15 may 
disrupt the function of other types of viral proteins that multimerize.  HIV Rev is a good 
candidate as it oligomerizes to form a complex that transports viral mRNAs out of the 
nucleus.  HIV Integrase would also be a good candidate because it is thought to function 
biologically as a tetramer and I have shown that it can be ISGylated.   
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Appendix I 
A1.1 EXPERIMENT I.: MUTATION OF THE ISG15 CONTACT SITES DISRUPTS ISG15 
CONJUGATION. 
The crystal structure of ISG15 identified several contact sites between the N-
terminal and C-terminal domains of ISG15 (Narasimhan et al., 2005).  These two 
domains contact each other via van der Waals interactions between N-terminal residues 
histidine 39 and phenylalanine 41 and the C-terminal residues proline 136 and glycine 
138.  We constructed an ISG15 C-terminal contact mutant (P136A/G138A) and an ISG15 
N-terminal contact mutant (H39A/F41A), and examined ISGylation when expressed in 
HEK293 cells along with Ube1L, UbcH8, and Herc5.  While the N terminal domain is 
not required for ISG15 conjugation (see Figure A2), disruption of the N contact sites 
reduces conjugation suggesting that, if the N terminal domain is improperly oriented, it 
can inhibit conjugation. The C contact mutations have a larger effect on conjugation, 
which could be due to a combination of a improper orientation and an effect on 
utilization of the C terminal domain by one or more enzymes of the pathway.   
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Figure A1. Mutation of the ISG15 contact sites. 
A) Structure of ISG15 (PDB 1Z2M).  The contact sites (dark blue) are indicated. 
B) HEK293 cells were transfected with plasmids expressing Ube1L, UbcH8, Herc5, and 
either wild type (WT), C-terminal contact mutant (C), or N-terminal contact mutant (N) 
FLAG-ISG15.  Cell extracts were prepared and analyzed by immunoblotting with anti-
FLAG antibody to detect ISG15 conjugates (top).  Expression of each FLAG-ISG15 
construct was confirmed by applying the same amounts of cell extracts as in the top to 
nitrocellulose using the Bio-Dot Apparatus (Bio-Rad) and blotting with anti-FLAG 
antibody (bottom). 
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A1.2 EXPERIMENT II:  ISG15-∆N CAN SUPPORT ISG15 CONJUGATION 
ISG15 consists of two Ub-like domains.  To begin to characterize the 
determinants on ISG15 required for the recognition by Ube1L and UbcH8, we 
determined the effect of deleting the N-terminal Ub-like domain of ISG15 (ISG15-∆N, 
deleted of residues 2-78).  ISG15-∆N was activated by wild-type Ube1L and transferred 
to UbcH8 in vitro (Figure A2A).  Furthermore, ISG15-∆N was conjugated to cellular 
proteins when expressed in HEK293 cells along with Ube1L, UbcH8, and Herc5 (Figure 
A2B).  As with wild-type ISG15, conjugation was dependent on Ube1L, UbcH8, and 
Herc5.  Conjugation of ISG15-∆N was slightly less efficient than with wild-type ISG15, 
although this may have been due to a reproducibly lower expression of ISG15-∆N 
compared to full-length ISG15 (not shown).  These results suggest the primary 
determinants of ISG15 recognized by all of the central components of the conjugation 
system are located within the C-terminal Ub-like domain of ISG15.  However, careful 
kinetic analyses of ISG15-∆N is needed at each step of conjugation to determine to 
determine the role of the N-terminal lobe of ISG15. 
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Figure A2: ISG15-∆N can support ISG15 conjugation. 
A) 32P-ISG15ΔN was incubated with Ube1L and either no E2, UbcH7, or UbcH8. 
Reaction products were analyzed by SDS-PAGE without reducing agent. An E2-
independent background band is indicated (*).  
B) 293 cells were transfected with plasmids expressing FLAG-ISG15 (lanes 1-4) or 
FLAG-ISG15ΔN (lanes 5-8) and with or without plasmids expressing Ube1L, UbcH8, 
and Herc5, as indicated. Lane 9 contained no ISG15-expressing plasmid. Cell extracts 
were collected and immunoblotted with anti-FLAG antibody. 
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A1.3 METHODS FOR APPENDIX I. 
Transfection Assays.  Human HEK293 cells were grown in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum.  Plasmid DNA transfections 
were performed with cells at 80% confluence using Lipofectamine transfection reagent 
(Invitrogen).  For the experiment shown in Figure A1B, plasmids expressing Herc5 (0.5 
µg), UbcH8 (0.25 µg), and Ube1L (0.25 µg) were transfected with either 1X-FLAG 
ISG15 wild type, C-terminal mutant, or N-terminal mutant (0.5 µg).  For the experiment 
shown in Figure A2B, plasmids expressing Herc5 (0.5 µg), UbcH8 (0.25 µg), and Ube1L 
(0.25 µg) were transfected as indicated with either 1X-FLAG ISG15 wild type or 1X-
FLAG ISG15-∆N (0.5 µg).  Cells were harvested and lysed 48 hours post-transfection in 
lysis buffer containing 1% Nonidet P-40, 100 mM Tris, pH 7.9, 100 mM NaCl, 1 mM 
DTT, 100 µM phenylmethylsulfonyl fluoride, 4 µM leupeptin, 0.3 µM aprotinin.  30 µg 
of total cell proteins were separated by SDS-PAGE, transferred to nitrocellulose 
membrane, and probed with anti-FLAG antibody (Sigma) to detect ISG15-conjugated 
proteins.  Alternatively, 30 µg of total cell proteins were applied to nitrocellulose using 
the Bio-Dot Apparatus (Bio-Rad) in the bottom of Figure A1B.   
Thioester Assay.  The experiment in Figure A2A was performed similarly to that 
in Figure 3.2 as described in Chapter 2.1 under biochemical assays except that the 
incubation time was 30 minutes.  32P-ISG15-∆N was prepared as described for 32P-ISG15 
in Chapter 2.1 as well. 
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